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Nonclassical Sex Hormone Signaling In Melanocytes And Melanoma
Abstract
The primary pigment in mammalian skin and hair is melanin, which is synthesized locally by differentiated
melanocytes and transferred into surrounding epidermal keratinocytes and hair shafts. Because
pigmentation differences are often readily visible clinically, melanocyte function is known to correlate with
changes in environment, as well as physiologic and pathologic changes in other organ systems. We
utilized these clinical associations to inspire the hypothesis that sex hormones influence melanocyte
biology. For over 2,000 years, it has been appreciated that pregnancy is associated with changes in skin
pigmentation, but the specific processes, hormones, receptors, and downstream signaling cascades
responsible have remained unknown. During this thesis work, we discovered that estrogen and
progesterone reciprocally regulate melanocyte pigmentation and differentiation state. We also
determined that melanocytes do not express classical nuclear estrogen or progesterone receptors, and
rather, sex hormones signal through two nonclassical G protein-coupled receptors: the G protein-coupled
estrogen receptor (GPER) and progestin and adipoQ receptor 7 (PAQR7). Specific activation of these
receptors with selective small molecule agonists that do not activate the nuclear hormone receptors,
recapitulates the entirety of the estrogen and progesterone effects in melanocytes. GPER and PAQR7
agonists may serve as new therapeutic agents for disorders of pigmentation. We then utilized the
discovery that GPER signaling drives differentiation in normal melanocytes to develop a novel
differentiation-based therapy for melanoma. Many lines of clinical evidence suggest that female sex and
history of prior pregnancies are associated with favorable melanoma outcomes, although the mechanism
for this presumed protective effect were previously unknown. We determined that GPER signaling in
melanoma cells drives a durable differentiation program that slows tumor growth, and renders tumor
cells more susceptible to clearance by the immune system. Systemic treatment of melanoma-bearing
mice with specific GPER agonists was well tolerated, and had dramatic combinatorial effects when
combined with immune checkpoint blockade, resulting in complete tumor clearance and long-term antitumor immunity. Thus, this work identified previously unknown mechanisms by which female sex steroids
influence melanocytes, and utilized that understanding to develop a novel melanoma therapy that
establishes, for the first time, the therapeutic benefit of combining differentiation drivers with cancer
immunotherapy.
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ABSTRACT
NONCLASSICAL SEX HORMONE SIGNALING IN MELANOCYTES AND MELANOMA
Christopher A. Natale
Todd W. Ridky
The primary pigment in mammalian skin and hair is melanin, which is
synthesized locally by differentiated melanocytes and transferred into surrounding
epidermal keratinocytes and hair shafts. Because pigmentation differences are often
readily visible clinically, melanocyte function is known to correlate with changes in
environment, as well as physiologic and pathologic changes in other organ systems. We
utilized these clinical associations to inspire the hypothesis that sex hormones influence
melanocyte biology. For over 2,000 years, it has been appreciated that pregnancy is
associated with changes in skin pigmentation, but the specific processes, hormones,
receptors, and downstream signaling cascades responsible have remained unknown.
During this thesis work, we discovered that estrogen and progesterone reciprocally
regulate melanocyte pigmentation and differentiation state. We also determined that
melanocytes do not express classical nuclear estrogen or progesterone receptors, and
rather, sex hormones signal through two nonclassical G protein-coupled receptors: the G
protein-coupled estrogen receptor (GPER) and progestin and adipoQ receptor 7
(PAQR7). Specific activation of these receptors with selective small molecule agonists
that do not activate the nuclear hormone receptors, recapitulates the entirety of the
estrogen and progesterone effects in melanocytes. GPER and PAQR7 agonists may
serve as new therapeutic agents for disorders of pigmentation. We then utilized the
discovery that GPER signaling drives differentiation in normal melanocytes to develop a
v

novel differentiation-based therapy for melanoma. Many lines of clinical evidence
suggest that female sex and history of prior pregnancies are associated with favorable
melanoma outcomes, although the mechanism for this presumed protective effect were
previously unknown. We determined that GPER signaling in melanoma cells drives a
durable differentiation program that slows tumor growth, and renders tumor cells more
susceptible to clearance by the immune system. Systemic treatment of melanomabearing mice with specific GPER agonists was well tolerated, and had dramatic
combinatorial effects when combined with immune checkpoint blockade, resulting in
complete tumor clearance and long-term anti-tumor immunity. Thus, this work identified
previously unknown mechanisms by which female sex steroids influence melanocytes,
and utilized that understanding to develop a novel melanoma therapy that establishes,
for the first time, the therapeutic benefit of combining differentiation drivers with cancer
immunotherapy.
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CHAPTER 1: THE DEVELOPMENT OF MELANOCYTES AND MELANOMA
OVERVIEW
Melanocytes are specialized cells responsible for producing pigment. While
melanocytes represent a minor cell population within the skin, they have a prominent
phenotype that is observable macroscopically. This has allowed biologists and
physicians to associate altered pigmentation with various environmental and physiologic
changes. Mutations affecting the amount of pigment produced, distribution of
melanocytes, and number of melanocytes all result in altered pigmentation and have
provided insight to the pathways responsible for melanocyte development and
differentiation. In addition to normal melanocyte homeostasis, the superficial location of
epidermal melanocytes has facilitated the study of melanoma, which enabled physicians
over hundreds of years to make observations that still influence our understanding of the
disease today. These clinical associations represent an invaluable resource for
understanding the biology of melanocytes, and have inspired research on both
melanocyte differentiation and melanomagenesis.

THE STRUCTURE AND ORGANIZATION OF THE SKIN
Generally, skin refers to the soft outer layer of tissue on vertebrates that is made
up of two layers, the epidermis and dermis. Together, these layers provide important
barrier functions that protect the underlying tissues from damage, including ultraviolent
radiation (UVR), pathogens, excessive water loss, and mechanical stress (Madison,
2003; Proksch et al., 2008). In addition, the skin has important functions in
thermoregulation (Romanovsky, 2014), sensation (Owens and Lumpkin, 2014), and
1

synthesis of metabolites like vitamin D (Piotrowska et al., 2016). The epidermis is the
outermost layer that consists of several layers of keratinocytes, and contains specialized
appendages including hair follicles, sweat glands and sebaceous glands. The dermis
resides below and consists primarily of fibroblasts and rich collagen networks. While all
vertebrates have skin, there are differences between species. For example, human skin
consists primarily of inter-follicular epidermis, with thickness ranging from 0.05mm to
1.5mm. Mice have vastly more hair follicles, and much thinner epidermis that is less than
0.025mm thick (Khavari, 2006).
Epidermis contains keratinocytes in varying stages of differentiation. The basal
layer of the skin is the least differentiated, and is thought to contain the epidermal stem
cells responsible for keratinocyte renewal. As keratinocytes on the basal layer divide,
they produce cells that lose contact with the basement membrane, and cease dividing in
the spinous layer. Above the spinous layer is the granular layer where differentiating
keratinocytes secrete lipids and lose nuclei and organelles as they terminally
differentiate. The outermost layer is referred to as the cornified layer, which consists of
many layers of terminally differentiated, dead keratinocytes containing dense networks of
keratins, ceramides, cholesterol, and fatty acids (Blanpain and Fuchs, 2009; Hsu et al.,
2014). While these layers of the epidermis provide the majority of the barrier functions
assigned to the skin, they do not provide protection from ultraviolet radiation (UVR). This
protection is provided by melanocytes, the pigment-producing cells of the epidermis.
Epidermal melanocytes are located within the basal layer of human skin where they
function to produce and transfer melanin pigment to surrounding keratinocytes.
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MELANOCYTE DEVELOPMENT
Melanocytes are derived from the neural crest, which also gives rise to neurons
and glia precursors, and delaminate from the dorsal section of the neural tube. These
precursor cells undergo an epithelial to mesenchymal transition as they continue to
migrate, proliferate, and differentiate (Mayor and Theveneau, 2013). In avian graft
models, it has been shown that neural crest precursors that initially migrate on a ventral
path from the neural crest are specified to develop into neurons and glia, while
precursors that migrate later on a dorsolateral path through the dermis develop into
melanocytes (Erickson and Goins, 1995). Migrating neural crest precursors have been
isolated and differentiated in vitro, where some isolates give rise to single cell-type
populations, while others produce mixed colonies of neurons, glia, and melanocytes.
Together, this suggests that while neural crest precursors are specified before exiting the
neural tube, there is some plasticity in the development of these lineages (Henion and
Weston, 1997).
The microphthalmia-associated transcription factor (MITF) is known as the
master regulator of melanocyte fate and identity (Baxter et al., 2010). MITF is a basic
helix-loop-helix leucine zipper transcription factor involved in lineage-specific pathway
regulation of many types of cells including melanocytes, osteoclasts, and mast cells
(Hershey and Fisher, 2004). There are at least nine different MITF transcript variants
present in humans, with MITF-M being the melanocyte specific transcript variant
(Hershey and Fisher, 2005). For this dissertation, “MITF” refers to the MITF-M, the
melanocyte-specific isoform of this transcription factor. MITF is necessary for the
development of melanocytes; mice and zebrafish lacking MITF orthologues fail to
3

develop melanocytes (Lister et al., 1999; Steingrimsson et al., 2004). Additionally, forced
MITF expression in embryonic stem cells and transformed fibroblasts induces
expression of melanocyte differentiation markers (Bejar et al., 2003; Tachibana et al.,
1996). Together, this suggests that MITF is both necessary and sufficient to drive
differentiation of melanocyte lineages during development. MITF mutations in humans
result in disrupted melanocyte development, resulting in Waardenburg syndrome type 2,
which is characterized by variable degrees of hearing loss and areas of patchy
hypopigmentation. Mutations in MITF are also causative in Tietz syndrome, which is
characterized by complete hearing loss and generalized hypopigmentation (Amiel et al.,
1998).
Generally, melanocyte precursors that express MITF are referred to as
melanoblasts. Melanocyte precursors begin to express MITF after WNT3A is
upregulated and bone morphogenetic protein 4 (BMP4) is downregulated in the
developing neural crest (Jin et al., 2001; Takeda et al., 2000). Other genetic syndromes
with pigmentation phenotypes served as clues to identify the transcription factors
responsible for the initial induction of MITF. Genetic analysis of Waardenburg syndrome
type 1 and type 4 have identified mutations in PAX3 and SOX10, respectively, as causal
in certain subsets of patients (Bondurand et al., 2000). PAX3 and SOX10 interact
synergistically to activate the expression of MITF (Potterf et al., 2000; Watanabe et al.,
2002); however, these two factors are also important for the development of glial cells
(Britsch et al., 2001; Jacob et al., 2014), suggesting that other factors may be involved in
the specification of the melanocyte lineage. Knockdown of FOXD3 results in an
expansion of MITF positive cells arising from the neural crest, as well as the presence of
4

melanocytes developing along nerves, suggesting that FOXD3 is a negative regulator of
melanocyte specification (Kos et al., 2001; Nitzan et al., 2013), and mechanistic studies
have identified FOXD3 as a repressor of MITF transcription regardless of the expression
of PAX3 and SOX10 (Curran et al., 2010; Curran et al., 2009; Thomas and Erickson,
2009). Similar results are observed when SOX2 is disrupted. SOX2 directly binds to the
MITF promoter and represses transcription, while conditional knockout in vivo drives a
glial fate-switch that expands MITF positive cell population (Adameyko et al., 2012). In
summary, the literature suggests that PAX3 and SOX10 are expressed in a common
glial-melanocyte, and repression of FOXD3 and SOX2 is required to specify the
melanocyte lineage.
After a small number of melanoblasts are specified within the neural crest and
begin expressing MITF, these cells expand rapidly and migrate large distances to
populate the epidermis, hair follicles, as well as other locations where specialized
subsets of melanocytes function like the ear and eye. In mouse embryos, biological and
mathematical modeling has determined that at embryonic day (E) 8.5 in mice, there is an
average of 16 founding melanoblasts that delaminate from the neural tube, which
expand

to

20,000

by

E15.5

(Luciani

et

al.,

2011).

Disruption

during

this

proliferative/migratory phase results in areas of the body lacking melanocytes and
pigmentation, which can occur in humans, mice, and other species (Fleischman et al.,
1991; Fontanesi et al., 2010; Hauswirth et al., 2012; Mills and Patterson, 2009). At E10.5
in mice, melanoblasts begin migrating dorsolaterally through the embryo, and begin
expressing melanocyte differentiation markers in addition to MITF, including DCT and
PMEL (Baxter and Pavan, 2003; Nakayama et al., 1998). Migration of melanoblasts has
5

been visualized using a number of methods including examination of pigmented and
unpigmented chimeras, and by rescuing tyrosinase expression in albino mice through
retroviral transduction (Huszar et al., 1991; McLaren and Bowman, 1969).
Melanoblast migration is regulated by a number of factors that are not required
for their initial specification, including regulators of cell adhesion. While in the neural tube
and prior to migration, melanocyte precursors express N-cadherin, a calcium-dependent
adherens junction protein. For delamination and subsequent migration to occur,
repression of N-cadherin is mediated through the expression of SLUG/Snail (in
chick/mice), which functions to activate the expression of N-cadherin (Jiang et al., 1998;
Nieto et al., 1994). As melanoblasts migrate through the dermis, most are epithelial and
placental cadherin negative (E- and P-), then begin to express E-cadherin as they
migrate to the epidermis (Nishimura et al., 1999). Other signaling pathways are also
necessary for the survival, migration, and proliferation of melanoblasts, such as the Gprotein-coupled receptor endothelin receptor type B (EDNRB) and receptor tyrosine
kinase, KIT. Expression of EDNRB and its ligand (endothelin B) between days E10.5
and E12.5 in mice is required for migration, and mutations in this pathway result in
disrupted migration (Lee et al., 2003; Shin et al., 1999). Similarly, mutations in KIT or its
ligand (KITL) also result in disrupted migration, producing spotted pigmentation and
other developmental defects (Yoshida et al., 1996). Melanoblasts express KIT, and KITL
is expressed in the surrounding microenvironment. During melanoblast migration,
dermatomal epithelial cells transiently express KITL, allowing for the movement of
melanoblasts through the dermis (Wehrle-Haller and Weston, 1995). Migration into the
epidermis requires expression of KITL on keratinocytes for melanoblasts to migrate into
6

the interepithelial space (Tabone-Eglinger et al., 2012). While differentiated melanocytes
are found in the inner ear, nervous system, heart, and likely elsewhere (Cichorek et al.,
2013), the remainder of this dissertation will focus on melanocytes within the epidermis.
In mice, the melanoblasts begin colonizing the epidermis by E15.5, concurrent
with the establishment of the primary hair follicle pattern (Mann, 1962). In hair follicles,
some melanoblasts differentiate into melanocytes that function to produce pigment in the
hair during the first hair cycle, while others remain as a melanocyte stem cell population
within the follicle (Nishimura, 2011). While there are not any specific markers for
melanocyte stem cells in the hair follicle, these cells are characterized by shape, location
in the follicle, low proliferative index, low levels of KIT and MITF expression, and overall
low transcription rate (Nishimura et al., 2002; Osawa et al., 2005). The melanoblast
population within the hair follicle divides to produce differentiated melanocytes offspring
as the hair cycle occurs (Ueno et al., 2014). In early postnatal mice, melanoblasts also
exist in the interfollicular space due to transient expression of KITL in mouse
keratinocytes. With the exception of the ear and tail skin, the expression of KITL
decreases a few days after birth, resulting in the loss of interfollicular melanoblasts in
mouse skin (Hirobe, 1984). Exogenous expression of KITL in keratinocytes within mouse
skin results in melanoblasts remaining in the skin and ultimately forming differentiated
melanocytes that function to produce epidermal pigment (Kunisada et al., 1998). In
humans, epidermal keratinocytes continue to express KITL and differentiated
melanocytes populate both the hair follicle and interfollicular space, resulting in
pigmentation of the hair and skin. In mice however, melanocyte populations largely exist
in the hair follicle. While the mechanisms through which melanoblasts migrate to the
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epidermis are partially understood, the sequence of events underlying terminal
differentiation of melanoblasts into interfollicular melanocytes is unknown. For the
remainder of this dissertation, I will focus on interfollicular melanocytes that function to
pigment the skin.
THE REGULATION OF EPIDERMAL PIGMENTATION
The primary role of differentiated, interfollicular melanocytes is to produce
pigment that is transferred to the keratinocytes within the skin. Melanocytes are located
in the basal layer of the epidermis, and each melanocyte is in contact with an estimated
30-40 surrounding keratinocytes. The density of melanocytes within the skin varies
across the body, ranging from ~2500 per mm2 on the face, ~900 per mm2 on the thigh,
and ~900 per mm2 on the upper arm (Fitzpatrick and Breathnach, 1963; Szabo, 1954).
Generally, the basal layer consists of a ratio of approximately 1:10 melanocytes to
keratinocytes. This ratio remains stable throughout human life as differentiated
melanocytes within the skin are thought to be quiescent and nonproliferative during
normal homeostatic conditions (Haass and Herlyn, 2005; Jimbow et al., 1975).
Both the type and amount of melanin pigment produced by melanocytes and
transferred to keratinocytes within the epidermis largely determine the color of human
skin (Matts et al., 2007; Thong et al., 2003). The synthesis and transfer of melanin is
referred to as melanogenesis, which primarily occurs within intracellular lysosome
related organelles within melanocytes called melanosomes. Maturation of melanosomes
occurs across four distinguishable stages. Stage I and II melanosomes are referred to as
early melanosomes, which lack pigment. Stage I melanosomes are small spherical
vesicles with a disorganized matrix, and stage II melanosomes are elongated and
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contain an organized fibrillar matrix. Stage III melanosomes contain pigment that is
deposited within the internal matrix, and stage IV melanosomes are characterized by
dense deposits of melanin covering the matrix fibrils (Kushimoto et al., 2001).
The synthesis of melanin occurs enzymatically by proteins regulated by the
master regulator of melanocyte differentiation, MITF, including but not limited to
tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and DOPAchrome tautomerase
(DCT). The initial substrate for melanogenesis is tyrosine, which is hydroxylated by TYR
to

L-3,4-dihydroxyphenylalanine

(DOPA),

and

is

subsequently

oxidized

into

DOPAquinone (Fitzpatrick et al., 1967). When cysteine is present, DOPAquinone reacts
and forms 3- or 5-cysteinyl-DOPAs, which non-enzymatically oxidize and polymerize
forming yellow/red soluble melanin known as pheomelanin (Simon et al., 2009). When
cysteine or other thiols are not present, DOPAquinone non-enzymatically undergoes
cyclization to DOPAchrome (Sugumaran, 1991), which spontaneously loses a carboxylic
acid forming 5,6-dihydroxyindole (DHI). DHI readily oxidizes to form dark brown/black
insoluble DHI-melanin. In the presence of DCT, DOPAchrome forms DHI-2-carboxcylic
acid (DHICA), which is further catalyzed by TYR and TYRP1 to form light brown DHICAmelanin (del Marmol and Beermann, 1996; Simon et al., 2009). While TYR, TYRP1, and
DCT are widely recognized as major mediators of melanogenesis, proteomic
characterization of this process have identified at least 600 proteins present at each
stage of melanogenesis, with 100 shared proteins present at each stage, suggesting that
there is still much to be understood about this process (Chi et al., 2006).
After the various types of melanin are synthesized in stage IV melanosomes, the
melanosomes are transferred to the surrounding keratinocytes. Within the melanocyte,
9

the melanosomes are trafficked from the perinuclear region to their dendritic projections
through dynein and kinesin-mediated microtubule intracellular transport (Watabe et al.,
2008). Mutations in pigment genes related to the trafficking of melanosomes underlie the
phenotypes of Griscelli syndrome (type I through III). As the melanosomes reach the
periphery of the cell, Rab27a, melanophilin, and myosin Va form a complex that links the
developed

melanosomes

to

F-actin

motors.

Rab27a

subsequently

binds

to

synaptogamin-like protein2-a, linking the melanosome to the plasma membrane prior to
exocytosis (Barral and Seabra, 2004; Van Den Bossche et al., 2006). The mechanisms
that underlie the transfer of melanosome from the melanocyte into the keratinocyte are
not completely understood. Models have been proposed suggesting that as the
melanosomes are exocytosed, they are wrapped in plasma membrane, forming
membrane pigment globules that contain multiple melanosomes. These globules are
then secreted into the extracellular space, where they are bound by the microvilli of
keratinocytes and are subsequently trafficked into the keratinocyte in a process that is
dependent on protease-activated-receptor-2. The surrounding membrane of the globule
is then degraded, allowing the release of melanosomes into the cytosol of the
keratinocyte, which are later trafficked to the perinuclear area (Ando et al., 2012; Ando et
al., 2011; Kobayashi et al., 1998).
The primary role of melanin in the skin is to protect the epidermis from ultraviolet
radiation (UVR).

UVR exists in two major forms on the earth’s surface, which are

referred to as UVA and UVB. 95% of the UVR spectrum is UVA, which causes damage
to DNA indirectly through the production of reactive oxygen species (ROS), while the
remaining 5% of the UV spectrum is UVB, which is capable of causing direct damage to
10

nucleotides (Briganti and Picardo, 2003; Maresca et al., 2006). The brown types of
melanin, DHI-melanin and DHICA-melanin, are collectively referred to as eumelanin and
considered to play a protective role when skin encounters UVR. Black skin from humans
of African decent contains 3 to 6-fold higher amounts of eumelanin than fair/white skin
(Ito and Wakamatsu, 2003); epidemiological studies support the conclusions that
eumelanin plays a protective role against UVR-mediated damage, as individuals with
black skin are 70 times less likely to develop skin cancer (Halder and Bang, 1988).
Eumelanin scatters UVR and limits penetration through the epidermis, resulting in
natural sun protection in black skin (Kaidbey et al., 1979). Studies examining the efficacy
of melanin as a sunscreen have determined that black skin is has approximately 2 sunprotection factors more than white skin, suggesting that black skin has twice the
protection from UVR. Melanosomes in dark skin also persist longer than melanosomes
in fair skin, which may significantly contribute to the photoprotective properties of black
skin. In addition to eumelanin serving to block UVR, it also plays a role as a free radical
scavenger and superoxide dismutase that reduce ROS, which further protects skin from
UVR (Bustamante et al., 1993). While brown melanin functions to protect the epidermis,
yellow/red melanin (pheomelanin) likely serves a contradictory role. Compared to
eumelanin, pheomelanin level is not correlated with skin tone and is more prone to
photodegradation (Slominski et al., 2004). When pheomelanin is degraded, it generates
hydrogen peroxide and superoxide anions, resulting in ROS that may cause mutations or
cell death in the melanocytes and surrounding cells (Chedekel et al., 1978; Harsanyi et
al., 1980; Hill and Hill, 2000). Thus, it has been suggested that while eumelanin plays a
protective role within the epidermis, pheomelanin may be a weak carcinogen.
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Both the amount and quality of melanin underlies the wide range in color of
human skin, which ranges from extremely light to very dark. The genetic determination of
baseline pigmentation is often referred to as constitutive pigmentation. Different types of
human pigmentation have been classified into a numerical system, known as the
Fitzpatrick scale (Fitzpatrick, 1988; Fitzpatrick and Breathnach, 1963). The scale
includes six categories as follows: type I skin, the starting point in pigmentation
differentiation, always burns in the sun and never tans, while type II usually burns, but
will tan minimally; type III and IV skin are referred to as intermediate skin tones that will
tan uniformly and well, respectively; type V skin is dark brown but still has the ability to
tan, and type VI skin is maximally pigmented and unable to tan any further. In mice, over
125 color loci have been identified, resulting in over 800 phenotypic alleles related to
pigmentation. Human orthologs for these loci have also been identified and are
frequently found to be loci for human disorders related to pigmentation, including
Waardenburg syndrome, Hermansky-Pudlak syndrome, and piebaldism (Bennett and
Lamoreux, 2003). Ancestral humans possessed body hair that offered protection from
UVR, and therefore lacked cutaneous pigmentation. Loss of body hair is thought to be
related the selection of traits that allowed better heat dissipation through sweating. As
ancestral humans lost their body hair, this presented a new selective pressure to
develop a means of protection from UVR, which ultimately led to the evolution of
interfollicular melanocytes and cutaneous pigmentation. Pigmented skin is somewhat
unique to humans, as many other mammals, including mice, do not have pigmented skin
(Jablonski and Chaplin, 2000). Pigmented skin offered several benefits over hairy skin to
ancestral humans beyond protection from UVR, including increases in the epidermal
permeability barrier as well as protection from UVR-mediated depletion of folate, a
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necessary metabolite for proper embryonic development (Elias et al., 2010; Jablonski
and Chaplin, 2010). While heavily pigmented skin was advantageous for ancestral
humans located in the tropics, as humans migrated to cooler climates dark pigmentation
was selected against. This is thought to be due to a combination of two selective
pressures: in areas with reduced UVR, there is less of a selective force for pigmentation
due to the reduced amounts of folate being degraded due to UVR; at the same time,
some UVR is required for the skin to produce vitamin D, therefore having reduced
pigmentation in northern climates could provide a selective advantage if this vitamin is
lacking in the diet (Jablonski and Chaplin, 2000). As humans migrated to different parts
of the globe, different single-nucleotide polymorphisms (SNPs) were selected for, which
ultimately resulted in a similar phenotype of reduced cutaneous pigmentation. In Europe,
selection for SNPs in solute carrier family 24 member 5 (SLC24A5), a calcium regulator
important for melanin production, and solute carrier family 45 member 2 (SLC45A2 or
MATP), a transporter for the melanin precursor tyrosine, underlie light pigmentation
(Ginger et al., 2008; Valenzuela et al., 2010). Variations in these solute carriers are
thought to represent 20-40% of the pigmentation difference between Europeans and
West Africans. SNPs in TYR, the rate-limiting enzyme in melanin synthesis, are found in
40–50% of Europeans and also South Asian populations (Norton et al., 2007; Stokowski
et al., 2007). In Asian populations, SNPs in oculocutaneous albinism II (OCA2), a
regulator of pH in melanosomes, are present in about half of the population (Donnelly et
al., 2012). Other SNPs in DCT, melanocortin 1 receptor (MC1R) and attractin are
considered candidate genes for future study that may also underlie light skin in Asian
populations (Myles et al., 2007; Peng et al., 2001). Together, this suggests that as
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humans migrated out of tropical climates, convergent evolution occurred at several
genetic loci that ultimately resulted in lighter skin tone.
While constitutive pigmentation contributes to the baseline color of human skin,
skin types between types II and V of the Fitzpatrick scale are able to change under
certain physiological context, which is referred to as facultative pigmentation. The most
significant example of facultative pigmentation is due to UVR, where exposure to
sunlight causes skin to darken in skin types II through V (Tadokoro et al., 2005). This
process occurs in two phases, immediate and delayed tanning responses. Immediate
tanning responses occur within hours of exposure and are due to the oxidization and
polymerization of existing melanin in the cell, as well as the redistribution of the melanin
to surrounding keratinocytes (Young, 2006). Delayed tanning response occurs after
repeated exposure to UVR and takes several days to occur. Delayed tanning involves a
change in the differentiation state of melanocytes, where UVR stimulates the expression
of MITF as well as downstream MITF targets that are essential for producing melanin
pigments, including Pmel17, MART-1, TYR, TRP1, and DCT (Miyamura et al., 2007).
This increase in melanocyte differentiation and pigment production is relatively stable, as
the tanned skin requires several months to return to the baseline pigment level, in
contrast to the immediate tanning response that dissipates in days (Coelho et al., 2009).
To respond to UVR to drive expression of MITF and downstream target genes,
melanocytes are dependent on melanocortin 1 receptor (MC1R), a G protein-coupled
receptor.
G protein coupled receptors (GPCRs) make up the largest family of
transmembrane signaling molecules and contribute to a variety of physiological and
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disease processes, including pigmentation, hematopoiesis, hemostasis, immune
function, metabolism, neurotransmission, reproduction, cardiac function, vascular tone,
differentiation, and cancer. In total, approximately 800 GPCRs have been identified in
the human genome, half of which are known as odorant/sensory receptors that have
restricted expression in specialized cells that detect external cues such as odors, tastes,
and pheromones. Non-odorant GPCRs are differentially expressed throughout all
tissues, and respond to a variety of ligands including peptides and small molecules.
While in vivo activities have been identified for ~350 non-odorant GPCRs, a significant
proportion of GPCRs remain orphans (Fredriksson et al., 2003; Joost and Methner,
2002). Non-odorant GPCRs make up a relatively large amount of the genome, about 1%,
but the expression levels of these same genes only make up 0.001-0.01% of all
expressed sequence tags, suggesting that this family of proteins are usually expressed
at relatively low levels (Fredriksson and Schioth, 2005). GPCRs transduce external
signals to the cell through heterotrimeric G proteins, which consist of alpha (α), beta (β)
and gamma (γ) subunits (Hurowitz et al., 2000). When a GPCR is activated, the α
subunit, a GTPase, exchanges a bound GDP for GTP that promotes the disassociation
from the β and γ subunits. The beta-gamma complex is known to interact with many
downstream effector molecules including ion channels, phospholipases, and kinases
(Clapham and Neer, 1997), but for the remainder of this dissertation I will focus on the
signaling events downstream of the α subunit. There are at least 20 different variants of
the α subunit, which can be separated into 4 families based on homology and
downstream activities. Generally, Gi-family functions to inhibit adenylate cyclase activity,
while the Gs-family functions to activate adenylate cyclase. The Gq-family activates
phospholipase C, and the G12/13-family activates the Rho family of GTPases (Albert and
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Robillard, 2002). Though it was originally thought that each GPCR interacted with a
distinct α subunit, GPCRs are sometimes able to differentially interact with several α
subunits depending on the conformational state of the receptor (Wenzel-Seifert and
Seifert, 2000).
MC1R is a Gs-coupled GPCR that is necessary for the pigmentation or tanning
response after skin is exposed to UVR. UVR exposure of keratinocytes promotes the
expression of proopiomelanocortin (POMC), a precursor of alpha melanocyte stimulating
hormone (αMSH), adrenocorticotropic hormone (ACTH), and β-endorphin (Schauer et
al., 1994; Tsatmali et al., 2000). The production of POMC and αMSH in keratinocytes is
dependent on a DNA damage response, and mice engineered to lack functional p53 in
keratinocytes fail to tan after UVR exposure, and p53 has been shown to both bind and
stimulate the transcription of POMC (Cui et al., 2007). αMSH produced after UVR
exposure binds and activates MC1R, which will subsequently stimulate adenylate
cyclase and downstream cAMP production (D'Orazio et al., 2006). Elevation of cAMP
activates protein kinase A (PKA), which leads to phosphorylation of cAMP responsiveelement-binding protein (CREB) transcription factor family members. CREB is known to
regulate the expression many genes, including MITF, which ultimately leads to the
production of proteins that promote melanogenesis after UVR exposure (Levy et al.,
2006). SNPs in MC1R that result in reduced function lead to a disruption in both
constitutive and facultative pigmentation, resulting in individuals with red hair and fair
skin that is unable to tan (Rouzaud et al., 2006).
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THE TRANSITION FROM NORMAL MELANOCYTE TO MELANOMA
Melanocytes play a vital role in producing pigment that protects the epidermis
from UVR-induced damage, ultimately conferring a resistance to formation of skin
cancers. This is supported by epidemiological data that shows that skin cancer
represents 35–45% of all neoplasms in Caucasians, 4–5% in Hispanics, 2–4% in
Asians, and 1–2% in those with African ancestry (Gloster and Neal, 2006; Ridky, 2007).
This suggests that the photoprotective effects of melanin that is produced by
melanocytes plays a large role in protecting the epidermis from skin cancer; however,
the melanocytes themselves are not immune to damage caused by UVR and are subject
to oncogenic transformation, resulting in melanoma. While basal cell and squamous cell
carcinomas represent the majority of skin cancer cases, melanoma is the most deadly
skin cancer (Glass and Hoover, 1989). The incidence of melanoma has risen faster than
any other type of cancer in developed countries since the 1950s, and the estimated
increase in the rate of melanoma in fair-skinned individuals has ranged from 3-7%
annually (Parkin et al., 2001; Thompson et al., 2005). The majority of melanoma arises
from sun-exposed skin, but melanoma can arise in places that are relatively protected
from UVR, such as the palms of the hands and soles of the feet (acral melanoma) and
mucosal surfaces (mucosal melanoma). In addition, melanoma can arise from other
tissues where melanocytes are present, including the uveal tract (Merkel and Gerami,
2017). The driver mutations present in cutaneous melanoma compared to these other
types vary (Curtin et al., 2005; Van Raamsdonk et al., 2009), and for the remainder of
this dissertation I will focus on cutaneous melanoma.
Generally, the term cancer refers to the abnormal proliferation of any cell within
the body, resulting in over 100 distinct known types of cancer. The development of
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cancer is a multistep process through which differentiated cells acquiring alterations that
progressively increase the cells capacity to proliferate, invade, and evade the immune
system. Included in these tumor-promoting alterations are genetic mutations that provide
a selective advantage to a cancer cell, whether it is a mutation that promotes proproliferative signaling in an oncogene, or eliminates the function of tumor suppressive
proteins. In addition to these genetic mutations, epigenetic alterations are also involved,
including a loss of cellular differentiation. Across many tissues, proliferation and
differentiation are inversely correlated such that as a cell differentiates, it loses the ability
to proliferate. As a differentiated cell transitions into cancer, it must bypass the normal
mechanisms of differentiation to reengage the cell cycle (Cooper, 2000; Reya et al.,
2001).
Given the typically pigmented nature and surface-level location, melanocytic
lesions have been characterized from the benign (common moles or nevi) to malignant
(melanoma) states. Idealized models of how normal melanocytes evolve to melanoma
consist of a progression from normal melanocyte into a benign nevus, then to a
dysplastic nevus, and finally to melanoma (Shain and Bastian, 2016). On average, fairskinned individuals have an average of 25 nevi that are 2-5mm in diameter, which arise
within the first 20 years of life and regress after 60 years (English et al., 1988; Zalaudek
et al., 2011). Due to their prevalence, individual nevi are unlikely to progress to
melanoma, but at least 20-50% of early stage melanoma is found to either be associated
with a nevus or have histological patterns representing a nevus (Shitara et al., 2014).
Nevi are formed when melanocytes undergo transient clonal growth after a BRAFV600E
mutation is introduced (Yeh et al., 2013). Acquired nevi are more commonly found on
sun-exposed areas, suggesting that UVR is an important factor in nevi formation even
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though the BRAFV600E mutation is not a UVR signature T to A transversion (Breitbart et
al., 1997). When the nevus reaches 2-5mm, proliferation ceases likely due to the TGF-βmediated induction of the tumor suppressive protein CDKN2B in the nevus (McNeal et
al., 2015). This growth arrest is described as senescence-like, and most nevi will not
change in size for many years (Michaloglou et al., 2005). When a nevus begins to show
signs of changes, it is referred to as a dysplastic nevus. Dysplastic nevi represent an
area of ambiguity in melanocytic neoplasms, as these lesions display both benign and
malignant features (Duffy and Grossman, 2012). Compared to benign nevi, dysplastic
nevi often have a higher mutational burden, proliferate slowly, and contain recurrent
TERT promoter mutation (Shain et al., 2015). Further supporting the idea that dysplastic
nevi are a precursor to melanoma, people with multiple dysplastic nevi have an
increased risk of developing melanoma at some point in their lifetime (Halpern et al.,
1993).
When melanocytes acquire the ability to proliferate and grow into irregular
patterns within the epidermis, these lesions are referred to as melanoma in situ. These
melanomas represent the earliest stage of the malignancy, and the survival rate is nearly
100% when these lesions are completely surgically resected (Balch et al., 2009; Guerry
et al., 1993). The growth of melanoma in situ occurs in two distinguishable patterns,
pagetoid growth and lentiginous growth. Pagetoid growth refers to the spread of
melanoma in either single cells or groups of cells throughout each layer of the epidermis,
while lentigous growth refers to the spread of melanocytes uniformly across the basal
epidermis (Viros et al., 2008). Melanoma in situ can arise from a preexisting nevus as
well as de novo, with no obvious association to a preexisting lesion. Typically, melanoma
that arises from preexisting nevi displays features of pagetoid growth (Shitara et al.,
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2014). Genetic analysis of melanoma in situ has identified alterations primarily in the
MAPK signaling pathway, including mutations in BRAF, NF1, and NRAS, as well as
TERT promoter mutations and heterozygous CDKN2 locus alterations (Shain et al.,
2015). It is thought that a significant amount of time is required to accumulate mutations
that form melanoma in situ, given that there is a relatively late age of onset (Menzies et
al., 2012). This idea is supported by the observation that melanoma in situ can persist
for many years before transitioning into invasive melanoma (Weinstock and Sober,
1987).
Invasive melanoma refers to melanoma cells that have invaded through
basement membrane into dermis. Most invasive melanoma develops from melanoma in
situ, and the depth of melanoma invasion correlates with the risk of metastatic disease
(Balch et al., 2009). Invasive melanoma forms when it undergoes additional genetic
mutations on top of the mutational landscape present in melanoma in situ. Invasive
melanomas often have homozygous deletions in the CDKN2 locus, resulting in the loss
of the p14ARF, p15, and p16 tumor suppressive proteins (Menzies et al., 2012). Some
invasive melanomas undergo mutations in the SWI/SNF chromatin-remodeling complex,
which acts as a tumor suppressor in many cancers (Hodis et al., 2012; Shain and
Pollack, 2013). In addition, late-stage invasive melanomas also have mutations in p53
and PTEN, which are both critical tumor suppressors involved in maintaining genomic
integrity and antagonizing pro-tumor AKT signaling (Birck et al., 2000; Castresana et al.,
1993). Accumulation of oncogenic mutations in melanoma ultimately results in cells that
are capable of disseminating from the local site that colonize other tissues. Metastatic
melanoma has the highest proliferative index of all stages of melanoma (Straume et al.,
2000). Generally, melanoma metastasizes to the peripheral lymph nodes near the
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primary tumor prior to transiting to distant visceral sites (Pasquali et al., 2012).
Phylogenetic analysis of primary and metastatic tumors has suggested that parallel
dissemination occurs where single or multiple cells simultaneously colonize distant sites
(Sanborn et al., 2015). It is still unknown whether specific mutations promote metastasis
of invasive melanomas, as large scale sequencing efforts have failed to identify recurrent
mutations (Gartner et al., 2012).
In addition to the key genetic events that occur as melanocytes transition into
melanoma, understanding of the disease has be generated from a developmental
prospective. Several studies have identified alterations in genes that regulate normal
melanocyte development, suggesting that developmental pathways that regulate
proliferation, migration, and differentiation may be deregulated in cancer (Shakhova,
2014; White and Zon, 2008). MITF plays a dual role in melanoma, where low levels of
expression promote proliferation, and high levels drive differentiation and cell cycle
arrest (Hoek and Goding, 2010). Melanoblasts are dependent on endothelin signaling
through EDNRB to proliferate and migrate during development, and EDNRB is
expressed in melanoma cells; inhibition of this receptor in melanoma cells reduces
proliferation and tumor growth (Lahav et al., 1999). Downstream signaling from EDNRB
causes a downregulation of E-cadherin, which may promote invasiveness of melanoma
(Bagnato et al., 2004). Wnt signaling plays an important role in melanoblasts
specification and survival, and overexpression of Wnt5a in melanoma promotes invasive
and motile phenotype that is necessary for metastasis (Bittner et al., 2000). Expression
of KIT in melanoblasts is required for migration into the epidermis, and expression of KIT
is often lost as cutaneous melanoma progresses (Natali et al., 1992). In general, factors
that are necessary for melanoblast migration and proliferation are upregulated in
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melanoma, and factors promoting the differentiation of melanocytes are downregulated,
fitting the paradigm of how cancer cells display features of developmental precursors of
the cell of origin. Together, this suggests that driving cellular differentiation could be an
effective therapeutic strategy in melanoma. Further understanding of pathways that drive
melanocyte differentiation may represent new pathways that could be targeted for
melanoma therapy.
It is clear that deregulation of melanocyte differentiation specific factors promotes
melanoma, but ubiquitously expressed factors related to cellular differentiation and
cancer also follow similar expression patterns. The protooncogene c-Myc was one of the
first oncogenes discovered and is found to be elevated in nearly 50% of all human
tumors (Nesbit et al., 1999; Sheiness and Bishop, 1979). c-Myc is a helix-loop-helixleucine zipper transcription factor that functions in dimer with MAX, binding to E- box
sequences (CACGTG) near transcription start sites in up to 15% of the genome
(Gearhart et al., 2007). c-Myc enhances tumorigenesis through induction of cell cycle
machinery, repression of cell cycle inhibitors, promotion of anchorage-independent
growth, metabolism, protein synthesis, angiogenesis, and chromosomal instability (Eilers
and Eisenman, 2008; Meyer and Penn, 2008; Oster et al., 2002). While these activities
have been widely described in the literature, one of the first activities of c-Myc was
identified to be the inhibition of cellular differentiation. In the 1980s, c-Myc expression
was found to inhibit chemically induced erythroid differentiation and Eμ-myc transgenic
mice were noted to have disrupted B cell development (Coppola and Cole, 1986;
Langdon et al., 1986). Since then, c-Myc activity has been found to be associated with
the inhibition of differentiation in a number of cell types, including hematopoietic,
adipocytic, neuronal, muscular, embryonic stem cells, etc. (Leon et al., 2009). The
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mechanism through which c-Myc represses cellular differentiation remains an open
question. It has been suggested that this effect may be related to the proliferationpromoting activities of c-Myc, as loss of proliferation and cell cycle exit is associated with
terminal differentiation. If cells with high levels of c-Myc remain in a proliferative state
with increased metabolism and protein synthesis, this may inhibit cellular differentiation
(Buttitta and Edgar, 2007). It has also been suggested that the c-Myc-mediated inhibition
of differentiation is independent of the proliferative effects. In neuronal-derived cell lines,
c-Myc expression inhibits differentiation without reversing the cell cycle arrest.
Microarray profiling of these cells did not identify an up regulation of cell cycle-related
genes, but rather down regulation of differentiation-associated genes, suggesting that
the activity of c-Myc may inhibit differentiation though mechanisms distinct from
proliferation (Acosta et al., 2008; Vaque et al., 2008). c-Myc expression is also known to
promote “stemness”, as evidenced by studies designed to generate induced pluripotent
stem cells. While c-Myc is not required for cellular reprogramming of an adult cell into a
pluripotent cell, it increases the efficiency of this process by at least 10-fold (Takahashi
et al., 2007; Welstead et al., 2008). c-Myc also binds to promoters of genes that promote
pluripotency, like OCT4 and SOX2 (Kidder et al., 2008). These activities related to dedifferentiation and “stemness” are likely important players in tumorigenesis as well.
About 20% of mice generated from induced pluripotent stem cells with c-Myc activation
develop cancer (Okita et al., 2007), and c-Myc is necessary for the development of skin,
intestine, and lung cancers (Sansom et al., 2007; Soucek et al., 2008).
In melanoma, the activation of c-Myc plays a clear role in the progression of the
disease. Through immunohistochemistry analysis, 43% of melanoma have detectable
nuclear c-Myc expression, and the level of expression is correlated with level of invasion,
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mitotic rate, and vertical growth (Lazaris et al., 1995). c-Myc expression in melanoma is
also associated with expression of the proliferation marker Ki67, and presence of these
markers is associated with decreased survival (Korabiowska et al., 1995). When
comparing primary to metastatic lesions, metastatic lesions had a higher level of c-Myc
expression, which was also associated with as shorter disease-free interval and reduced
survival (Grover et al., 1997; Ross and Wilson, 1998). In addition to c-Myc’s roles in
proliferation and differentiation, it also plays a role in how the tumor cell interacts with the
immune system. HLA (in humans) or MHC (in mice) class I molecules are found on the
cell surface of all nucleated cells in vertebrates, and function to display peptides on the
surface. Displaying peptides allows the immune system, namely cytotoxic T cells, to
recognize antigenic peptides and trigger an immune response (Kulski et al., 2002;
Whitbeck et al., 1991). Loss of HLA class I expression

in tumor cells prevents the

immune system from recognizing them, and is a common mechanism of immune cell
evasion (Kulski et al., 2002). In melanoma and other tumors, the expression of c-Myc
and HLA class I is inversely correlated (Peltenburg et al., 1993; Versteeg et al., 1988),
suggesting that c-Myc negatively regulates expression of these receptors. In addition, cMyc also regulates the expression of immune checkpoint regulator molecules in tumor
cells. Immune checkpoint regulators function to suppress immune responses, and tumor
cells express these molecules to evade the immune system (Pardoll, 2012). c-Myc
activates the expression of immune checkpoint regulators, such as PD-L1 and CD47,
which promotes the evasion of the immune system (Casey et al., 2016; Kim et al., 2017).
Together, this suggests that c-Myc promotes melanoma progression through a number
of pathways, including driving proliferation, inhibiting differentiation, and aiding in
immune evasion.
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THE MANAGEMENT OF ADVANCED MELANOMA
Throughout history, medical providers struggled with the management of
advanced melanoma, which is considered the most deadly form of skin cancer in current
times (Howlader et al., 2013). The first known occurrence of melanoma dates back to
~2400 BCE and was observed as the presence of diffuse melanotic metastases on Inca
mummies (Urteaga and Pack, 1966). The first mentions of melanoma in the medical
literature dates back to the time of Hippocrates in the 5th century BCE, and later by the
Greek physician Rufus of Eupheses in ~60–120 CE. Later, from 1650-1760, melanoma
began to be mentioned several times in the European medical literature by Highmore,
Henrici, and Nothnagel, who made references about “fatal black tumors with metastases
and black fluid in the body”. In 1787, John Hunter at St. George’s Hospital Medical
School in London performed the first surgical removal of melanoma. The excised lesion
was described as “soft and black” and as “cancerous fungous excrescence”. Although
Hunter was unaware that this lesion was melanoma, the preserved lesion was
retroactively diagnosed in 1968 (Bodenham, 1968). At this point in time, physicians were
not distinguishing between black carbon deposits and pigmented melanoma lesions in
tissues. In 1806, Rene Laennec described “melanose” tumors as a distinct disease form
these carbon deposits (Roguin, 2006). The disease progression of melanoma was not
understood until 1820 when Dr. William Norris followed a melanoma patient over three
years. Over this time period, aspects of disease progression were monitored until the
patient succumbed to their disease. In addition to documentation of melanoma etiology,
he also made one of the first connections of melanoma being a heritable disease, as this
patient’s father also died from melanoma and other members of this family had
numerous nevi on their bodies (Greene et al., 1984). Later in 1857, Norris built on his
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initial observations in more cases of melanoma and determined general principles of
epidemiology and clinical management, proposing links between melanoma and nevi,
light skin tone, environmental pollution (Greene et al., 1984).
Management of melanoma throughout the 1800s consisted of surgical removal of
tumors, ligature, amputation, chloride of zinc, or the use of caustic agents to burn tumors
away. Around the 1850s, surgical anesthesia had become available and began being
used to render patients “insensible” prior to surgery for the removal of melanoma
(Furgusson, 1851). In 1892, Herbert Snow believed that excision of the primary tumor
was insufficient to treat the disease, and that the removal of the regional lymph nodes
was also required (Snow, 1892). While this work formed the basis of treating melanoma
through surgical resection, it offered very little insight into the etiology or mechanistic
basis for the disease (Essner et al., 2004). Later in 1966, Wallace Clark developed a
standard scale based on histology that correlated with prognosis and treatment. This
was referred to as “Clark’s Levels,” which were defined by the depth of invasion. In 1970,
Alexander developed a similar system related to both the tumor size and depth of
invasion, known as the Breslow thickness. These two systems are still used today, as
tumor thickness is a major prognostic factor for localized melanoma (Balch et al., 2009).
These staging systems increased the quality of care for patients with melanoma, as it
informed physicians of the size of margins required when performing the surgical
removal of melanoma (Breslow and Macht, 1977). While surgery was an effective
treatment for early-stage melanoma, and is still to this day, treatment of advanced
melanoma has proved to be far more difficult. Early attempts to treat advanced
melanoma relied on using agents that were highly toxic and immunosuppressive. In
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1968, a study was published describing the use of inter-arterial melphalan as an
effective treatment for melanoma (Bodenham, 1968). Melphalan is a chemotherapy drug
in the family of nitrogen mustard alkylating agents, and the utility of this drug was limited
by toxicity and short-duration of action. The alkylating agent dacarbazine was FDAapproved as the new standard treatment for advanced melanoma in 1975, even though
it was only associated with partial responses and an overall survival of about one year
(Yang and Chapman, 2009). An immunotherapy approach, high-dose interleukin-2, was
approved in 1992, although it was not effective in large numbers of patients and was
associated with high levels of toxicity (Atkins et al., 1999). Ultimately, none of these
therapeutic approaches resulted in robust or durable therapeutic responses in advanced
melanoma.
The 21st century brought new progress as information from laboratory
investigations were integrated to better identify therapeutic interventions for advanced
melanoma. In 2002, genetic screening in melanoma identified activating BRAF mutations
occurring in the majority of cutaneous melanoma, and most of these mutations were a
single amino acid substitution of valine for glutamic acid at position 600 (BRAF V600E)
(Davies et al., 2002). This mutation results in constitutive activation of BRAF, resulting in
sustained downstream MAPK signaling that drives tumor progression. Mutant BRAF has
since been shown to be the major oncogenic driver in 50% of melanomas (Wellbrock et
al., 2004). Activating mutations in BRAF are also found in benign nevi, providing a
solidified link between nevi and melanoma that was originally suggested in the 1800s
(Pollock et al., 2003). The identification of a specific mutation in BRAF underlying a large
percentage of melanomas led to the development of pharmacologic agents to target this
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protein. Initially, low potency inhibitors of mutant BRAF, like sorafenib, were shown to be
well tolerated but had arguably no anti-tumor activity as a monotherapy, leading to
skepticism surrounding this approach (Eisen et al., 2006). Further medicinal chemistry
was performed to create mutant BRAF inhibitors with higher specificity, resulting in the
development of vemurafenib (Tsai et al., 2008). This agent showed great promise in
preclinical models of melanoma (Bollag et al., 2010), and progressed rapidly through
early phase clinical trials resulting in striking tumor shrinkage in patients with BRAFV600E
positive melanoma (Flaherty et al., 2010). In a large scale, randomized phase III trials,
vemurafenib was tested against the current standard of care, dacarbazine. The results of
this trial were so striking that it was stopped early after vemurafenib showed a clear
survival benefit with the overall response rate being 48% compared to 5% for
dacarbazine (Chapman et al., 2011). These successful trials led to the FDA approval of
vemurafenib in 2011, the first FDA-approved agent for a specific mutation in melanoma.
While there was tremendous success initially, these impressive responses were not
durable and most patients developed resistance and progressed on this therapy
(Fedorenko et al., 2011). Several resistance mechanisms to BRAF inhibition have been
documented in melanoma, including BRAF truncations, alterations in receptor tyrosine
kinase signaling, NRAS mutations, and MEK mutations (Wagle et al., 2011). Recent
reports have suggested that elevation of ARAF and CRAF can overcome BRAF
inhibition in melanoma, leading to resistance (Montagut et al., 2008). The use of
selective kinase inhibitors to treat cancer is fading in favor for the current wave of
therapeutic approaches that utilize the immune system.
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While early immunotherapy approaches like IL-2 showed limited efficacy, it has
been clear since the 1950s that sometimes melanoma undergoes spontaneous
regression that may be immune-mediated (Sumner, 1953). As the understanding of the
immune system has expanded, this information has been leveraged in the field of cancer
therapy to drive immune responses against tumors. To prevent the immune system from
becoming hyper-activated and causing harm to normal tissues while responding to
antigens, immune checkpoint proteins have evolved to buffer the immune response. In
cancer, the same mechanisms can be harnessed to allow the tumor cells to evade the
immune system (Pandolfi et al., 2008; Stewart and Smyth, 2011). New therapeutic
approaches have applied this understanding to target immune checkpoint proteins,
namely CTLA4 and PD-1, as a powerful immunotherapy approach to treat cancer. For a
T cell to become activated to target tumor cells, it must first learn to recognize an antigen
present within the tumor and also that this antigen represents something deleterious. A T
cell becomes educated of antigens by interactions with the T cell receptor (TCR)
recognizing peptides present in HLA/MHC molecules on either the tumor cell or antigenpresenting cells. For a response to be generated, the tumor cell or antigen-presenting
cell must also present the B7 costimulatory molecule. B7 is bound by CD28 on the T cell,
which functions as a stimulatory signal for the T cell. B7 is also bound by CTLA4 on the
T cell, which functions to compete with CD28 for B7 binding and inhibits T cell activity
(Stewart and Smyth, 2011). Other negative regulatory circuits also exist during T cell
activation. PD-1 is a cell surface receptor on T cells that binds PD-L1, which is
expressed on the surface of antigen-presenting cells and cancer cells. PD-1 activation
inhibits T cell activation and ultimately leads to T cell depletion, negatively regulating the
immune response to tumor cells (Merelli et al., 2014). These immune checkpoint
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proteins are typically activated in the melanoma tumor microenvironment, and have
proved to be important therapeutic targets in melanoma (Kyi and Postow, 2014).
Targeting these immune checkpoint proteins, CTLA4 and PD-1, with monoclonal
antibodies that block their activity is thought to “take the brakes” off the immune system
and activates responses that are otherwise repressed in the tumor microenvironment.
When these interventions are successful, 20-50% of patients respond and some even
have complete responses, resulting in remission from melanoma (Robert et al., 2015).
While immune checkpoint inhibitors represent a transcendental shift in the management
of melanoma, understanding why some patients do not respond, how to increase the
response rate, and how resistance is formed remains open questions. For T cells to
recognize and target cancer cells, proteins within cancer cells must be processed and
presented in the context of HLA molecules, suggesting that downregulation of HLA
molecules could be a mechanism through which cancer cells use to continue to evade
the immune system in the presence of immune checkpoint inhibitors. Accordingly,
patients without HLA expression in their melanoma tumors fail to respond to
immunotherapy, and other studies have validated that HLA loss is an escape
mechanism for immunotherapies (Restifo et al., 1996; Zaretsky et al., 2016). In order for
HLA molecules to signal to the immune system, they must be loaded with a peptide that
can be recognized as an antigen. Theoretically, peptides can only be recognized as an
antigen if they contain a mutation that allows the immune system to determine that the
peptide is different from any other “self” peptides, which are referred to as neoantigens.
High mutational loads in melanoma have been correlated with the efficacy of immune
checkpoint inhibitors, but no recurrent patterns in neoantigen expression have been
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established (Van Allen et al., 2015; van Rooij et al., 2013). Immune-related adverse
events are a limitation of this therapeutic approach (Larkin et al., 2015), but have
suggested mechanisms through which the immune system is recognizing melanoma.
Melanoma patients that are responding well to immunotherapy often develop vitiligo,
which is an autoimmune attack on normal melanocytes present within the skin (Gogas et
al., 2006; Hua et al., 2016). This suggests that rather than the immune system reacting
to a neoantigen in the tumor, it recognizes a normal melanocyte protein as an antigen,
and targets melanoma cells as well as the normal melanocytes. In vitiligo, it is known
that T cells can recognize normal melanocyte differentiation proteins like MC1R and
tyrosinase as antigens (Kemp et al., 2002; Song et al., 1994). Driving expression of
these antigens through stimulation of melanocyte differentiation may represent an
effective combination therapy to be used in conjunction with immunotherapy.
THESIS OBJECTIVES
The overarching objective of this thesis is to use clinical observations to inspire
testable hypotheses regarding melanocyte homeostasis. For many years it has been
suggested that there are associations between sex hormones, melanocyte activity, and
melanoma progression, yet the specific hormones, receptors, and downstream signaling
cascades have remained elusive. In chapter 2, we examine the clinical associations
between pregnancy and hyperpigmentation to answer the question of how sex hormones
influence melanocyte differentiation and pigmentation, and identify estrogen and
progesterone as molecules that upregulate and downregulate melanocyte pigmentation,
respectively. We identify that these sex hormones signal through nonclassical GPCRs to
access canonical differentiation pathways. In chapter 3, we target the nonclassical
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estrogen receptor GPER as a differentiation-based therapy in melanoma, including a
mechanistic analysis identifying c-Myc as a central mediator of the effects. GPER
activation in combination with immune checkpoint blockade results in effective tumor
clearance with long-lasting tumor immunity. In chapter 4, we discuss how the biology
described in the previous chapters can be built upon to further understand melanocyte
homeostasis as well as how it can be applied to different tissue types and other
physiological contexts.
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CHAPTER 2: SEX STEROIDS REGULATE SKIN PIGMENTATION THROUGH
NONCLASSICAL RECEPTORS

Parts of this chapter have been previously published in:
Natale, C. A., Duperret, E. K., Zhang, J., Sadeghi, R., Dahal, A., O’Brien, K. T.,
Cookson, R., Winkler, J.D., Ridky, T. W. (2016). Sex steroids regulate skin pigmentation
through nonclassical membrane-bound receptors. eLife, 5, e15104.
http://doi.org/10.7554/eLife.15104
OVERVIEW
The association between pregnancy and altered cutaneous pigmentation has
been documented for over two millennia, suggesting that sex hormones play a role in
regulating epidermal melanocyte (MC) homeostasis. Here we show that physiologic
estrogen (17β-estradiol) and progesterone reciprocally regulate melanin synthesis. This
is intriguing given that we also show that normal primary human MCs lack classical
estrogen or progesterone receptors (ER or PR). Utilizing both genetic and
pharmacologic approaches, we establish that sex steroid effects on human pigment
synthesis are mediated by the membrane-bound, steroid hormone receptors G proteincoupled estrogen receptor (GPER), and progestin and adipoQ receptor 7 (PAQR7).
Activity of these receptors was activated or inhibited by synthetic estrogen or
progesterone analogs that do not bind to ER or PR. As safe and effective treatment
options for skin pigmentation disorders are limited, these specific GPER and PAQR7
ligands may represent a novel class of therapeutics for disorders of pigmentation.
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INTRODUCTION
Cutaneous pigmentary changes have been long recognized as common side
effects of pregnancy. The British physician Daniel Turner, in his 1714 De Morbis
Cutaneis (Turner, 1726), references Hippocrates (460-370 B.C.E.), “There is a spot on
the face…more peculiar, according to our great master Hippoc., to Big Belly’d women,
and recon’d as one of the Signs of Conception.” Modern physicians recognize this
common pregnancy-associated hyperpigmentation as melasma (Figure 2.1-figure
supplement 1A-C) (Nicolaidou and Katsambas, 2014; Sheth and Pandya, 2011).
Hippocrates also thought that the pigment was predictive of the sex of the fetus: Quae
utero gerentes, maculum in facie veluti ex solis adustione habent, eae faemellas
plerumque gestant. Translated to English: pregnant women who have a mark on the
face as though stained by the sun, quite often give birth to girls. While Turner noted this
association with fetal sex to be “fallible”, Hippocrates was remarkably astute in linking
the pigment increases to the tanning response to DNA-damaging solar ultraviolet (UV)
radiation. While early physicians attributed the pigment changes to “Retention of the
menstrual Flux” (Turner, 1726), the molecular mechanisms through which pregnancyassociated hormonal changes modulate skin color have remained elusive for over 2,000
years.
Melanocytes in the basal epidermis control skin pigmentation through synthesis
of melanin, a complex process thought to be primarily regulated by alpha-melanocyte
stimulating hormone (αMSH) (Figure 2.1-figure supplement 2A and B). The αMSH
peptide is secreted centrally by the anterior pituitary gland, and locally by keratinocytes
in response to UV damage (Cui et al., 2007). αMSH binding to the melanocortin receptor
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1 (MC1R), a G protein-coupled receptor (GPCR), activates adenylate cyclase, and
increases cAMP. This secondary messenger activates a cascade of downstream
transcriptional events leading to expression of genes required for melanin synthesis
(Rodriguez and Setaluri, 2014). Exogenous broadly-acting adenylate cyclase activators
such as plant-derived forskolin, also stimulate melanin production (D'Orazio et al., 2006),
but the degree to which other endogenous molecules, other than αMSH regulate melanin
synthesis in tissue is unclear. However, the observation that melasma frequently occurs
in non-pregnant women using oral contraceptive pills, which contain only steroid
hormone analogs (Resnik, 1967b; Sheth and Pandya, 2011), suggests that humans may
maintain αMSH-independent pigment control mechanisms. Identifying these pathways,
and strategies to specifically access them pharmacologically to modulate skin
pigmentation, may have substantial therapeutic utility.
RESULTS
To examine whether sex steroids influence melanin synthesis, we treated primary
human melanocytes with estrogen (17β-estradiol). This resulted in a dose-dependent
melanin increase (Figure 2.1-figure supplement 2C). After 4 days of exposure to 25 nM
estrogen, a medically-relevant concentration observed during pregnancy (AbbassiGhanavati et al., 2009), melanin was markedly increased (208% +/- 27%) in three
individual isolations of primary human melanocytes (Figure 2.1A). The magnitude of this
change was similar to that observed with αMSH (Figure 2.1-figure supplement 2D), and
is consistent with a prior in vitro studies implicating estrogen in melanin synthesis
(McLeod et al., 1994; Ranson et al., 1988). Hormonal oral contraceptives, most of which
incorporate ethinyl estradiol, are associated with melasma (Resnik, 1967a). Ethinyl
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estradiol also increased melanin to levels similar to those observed with native estrogen
(Figure 2.1-figure supplement 2E). To examine the effects of estrogen on melanocyte
homeostasis in the context of intact human epidermis, architecturally-faithful threedimensional organotypic skin was established utilizing normal primary epidermal
keratinocytes and melanocytes in native human stroma (Duperret et al., 2014; McNeal et
al., 2015; Monteleon et al., 2015; Ridky et al., 2010). After one week, estrogen-treated
skin displayed a 3-fold increase in melanin content (Figure 2.1B), without changes in
melanocyte number or density (Figure 2.1C).
Estrogen effects in other tissue types are often counter-balanced by
progesterone (Ismail et al., 2015b), which also increases during pregnancy. To
determine whether this reciprocal relationship is active in melanocytes, we treated cells
with physiologic levels of progesterone, which resulted in a dose-dependent decrease in
melanin production (Figure 2.1-figure supplement 2F). At 500 nM, a concentration
observed in third trimester pregnancy (Abbassi-Ghanavati et al., 2009), progesterone
decreased melanin production by half (58% +/- 11.4%), both in culture (Figure 2.1D) and
in skin tissue (Figure 2.1E), without altering melanocyte cell number (Figure 2.1F). Most
of our primary melanocytes were derived from newborn male foreskin. To determine
whether female cells also responded similarly, we treated female iPS-derived
melanocytes with estrogen and progesterone and noted responses similar to those
observed with the male cells (Figure 2.1-figure supplement 2G). To determine whether
melanocytes isolated from body sites other than foreskin also responded similarly to sex
hormones, we treated melanocytes from adult facial skin with estrogen and progesterone
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and again observed responses that were similar to those observed with the foreskin
melanocytes (Figure 2.1-figure supplement 2H).
Consistent with other groups who have noted that steroid hormones have
variable effects on melanocyte proliferation in culture (Im et al., 2002), we observed
modest changes in proliferation when isolated primary cells were treated with estrogen
or progesterone in vitro. Estrogen treated melanocytes tended to proliferate slightly
slower, while progesterone treated cells tended to proliferate slightly faster (Figure 2.1figure supplement 3A-B). The effects varied with basal level of melanin production.
Melanocytes from dark skin were more sensitive to progesterone than estrogen, while
melanocytes from light skin were more sensitive to estrogen. These proliferation
changes are likely an in vitro artifact, as adult interfollicular epidermal melanocytes are
relatively nonproliferative in vivo, and we did not note any changes in melanocyte
numbers in sex steroid-treated 3-D organotypic tissues. Consistent with this lack of
melanocyte proliferation in interfollicular epidermis, another group thoroughly examined
280 tissue sections from normal human skin from 18 donors, and identified only 2
proliferative interfollicular melanocytes (Jimbow et al., 1975).
To determine the mechanisms mediating estrogen and progesterone pigment
effects, we examined components of the canonical pigment production pathway, and
observed a cAMP increase upon estrogen treatment (Figure 2.2A), suggesting that
estrogen accesses the canonical pigment production pathway downstream of MC1R.
Consistent with this, p-CREB and MITF proteins were similarly induced (Figure 2.2B). In
contrast, progesterone reciprocally decreased melanin, cAMP, p-CREB and MITF
(Figures 2.2C-D).
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These data indicate that estrogen, progesterone, and αMSH converge on
adenylate cyclase to reciprocally modulate melanin synthesis, and suggest that
individual steroid effects may counter-balance each other. Consistent with this, the
estrogen effects were significantly attenuated in the presence of progesterone (Figure
2.2E). This likely helps explain why pregnancy-associated hyperpigmentation is
characteristically limited to specific areas where melanocyte or UV radiation exposure is
highest including the face, genital, and areolar regions (Staricco and Pinkus, 1957;
Szabo, 1954). It is also possible that in the complex hormonal milieu of pregnancy,
additional factors beyond the sex steroid activated pathways described here also
contribute to skin color modulation.
As steroid hormones are not predicted to signal through MC1R, whose natural
ligand is the peptide αMSH, we sought to identify the specific receptors mediating the
estrogen and progesterone pigment effects. We did not detect classical estrogen (ER) or
progesterone (PR) receptors in melanocytes using qRT-PCR, although transcripts were
observed in breast cells (Figure 2.2-figure supplement 1A). Previous RNAseq studies in
human melanocytes, conducted for unrelated experimental questions (Flockhart et al.,
2012), also failed to detect ER or PR transcripts (Figure 2.2-figure supplement 1B).
Consistent with this, ER or PR protein was not observed in MC via western blotting,
although both receptors were readily apparent in breast cells (Figure 2.2F).
Considering MC1R is a G protein-coupled receptor (GPCR), we hypothesized
that alternative GPCRs mediate sex steroid pigment effects. To identify possible
candidates, we analyzed whole transcriptome melanocyte RNAseq data. Of 412 known
or predicted 7-pass human GPCRs (Alexander et al., 2013), 61 distinct GPCRs were
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expressed in MCs, including the membrane-bound, G protein-coupled estrogen receptor
(Filardo et al., 2002) (GPER) (Figure 2.2-figure supplement table 1 and Figure 2.2-figure
supplement 1B). Given that prior work in breast cancer cell lines and fish oocytes
determined that estrogen binding to GPER modulates cAMP (Cabas et al., 2013; Filardo
et al., 2002; Majumder et al., 2015; Pang and Thomas, 2010; Thomas et al., 2005), and
that cAMP signaling stimulates melanin synthesis, we thought it possible that GPER may
be the physiologically relevant human melanocyte estrogen receptor. The melanocyte
RNAseq studies also demonstrated that an analogous, noncanonical G protein-coupled
progesterone receptor, progestin and adipoQ receptor 7 (PAQR7) (Tang et al., 2005;
Zhu et al., 2003), was also expressed (Figure 2.2-figure supplement 1B). We next used
qRT-PCR to verify that GPER and PAQR7 are both expressed in primary human MC
(Figure 2.2-figure supplement 1C). Notably, GPER and PAQR7 expression was
markedly lower in other skin cells including keratinocytes and fibroblasts (Figure 2.2figure supplement 1D).
To establish the necessity of GPER and PAQR7 in mediating sex hormone
effects in MCs, we first depleted GPER using either of two independent shRNA hairpins,
which completely eliminated the melanocyte pigmentation response to estrogen (Figure
2.2G and Figure 2.2-figure supplement 1E-F). Analogous shRNA-mediated PAQR7
depletion ablated the pigmentary response to progesterone (Figure 2.2H and Figure 2.2figure supplement 1F). To verify these results, we next used a complementary genetic
approach based on CRISPR-Cas9 mediated gene disruption of GPER or PAQR7, which
also completely blocked the pigmentary response to estrogen and progesterone,
respectively (Figure 2.2-figure supplement 1G-H). Consistent with our model in which
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these receptors access melanin synthesis at the level of adenylate cyclase, PAQR7 was
found to bind progesterone and regulate the final stages of sea trout oocyte meiosis
through cAMP reduction (Tokumoto et al., 2012; Zhu et al., 2003). In that fish system,
PAQR7 signals through G protein complexes containing the inhibitory G subunit (Gi),
which represses adenylate cyclase. To examine whether this signaling mechanism is
functional in melanocytes, we treated melanocytes with progesterone in the presence of
pertussis toxin (PTX), an exotoxin that specifically inactivates Gi subunits via ADPribosylation. With PTX treatment alone, we observed a small increase in melanin
production. This likely reflects inhibition of Gi released from basal PAQR7 activity, as
well Gi subunits from other GPCRs that collectively contribute to the basal level of cAMP
signaling observed in culture. Importantly, PTX blocked progesterone effects,
establishing that progesterone signals through Gi subunits (Figure 2.2-figure supplement
2A).
To complement these genetic studies establishing that GPER and PAQR7 are
the melanocyte sex steroid receptors, we utilized a pharmacologic approach employing
synthetic steroid analogs with specific agonist or antagonist activity on ER, PR, GPER,
or PAQR7. Tamoxifen, an ER antagonist, is associated with melasma in breast cancer
patients (Kim and Yoon, 2009). The mechanistic basis for the pigment change was
previously unknown. However, tamoxifen is a GPER agonist (Li et al., 2010; Thomas et
al., 2005), and increased melanin to levels comparable to those observed with estrogen
(Figure 2.3-figure supplement 1A). To determine whether GPER signaling was sufficient
to increase melanin, we utilized the specific GPER agonist G-1 (Bologa et al., 2006), an
estrogen analog developed for mechanistic studies in other systems that does not bind
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ER. G-1 drove a dose-dependent increase in melanin production through p-CREB and
MITF that was GPER dependent (Figure 2.3A-C and Figure 2.3-figure supplement 2AD).

Further establishing that GPER is the melanocyte estrogen receptor, G-1 and

estrogen effects were blocked by either of two specific GPER antagonists, G-15 and G36 (Figure 2.3-figure supplement 2E), which do not have inhibitory activity against ER
(Dennis et al., 2009; Dennis et al., 2011). To establish that PAQR7 signaling is sufficient
to decrease melanin production, we used a specific PAQR7 agonist Org OD-02
(CH2P4), which does not bind PR (Kelder et al., 2010). CH2P4 caused a dosedependent decrease in melanin production through p-CREB and MITF that was PAQR7
dependent (Figure 2.3D-F and Figure 2.3-figure supplement 3A-D).
To demonstrate that GPER was sufficient to promote melanin production in vivo,
we synthesized G-1 to 95% purity (Figure 2.4-figure supplement 1A-B), and formulated
G-1 for topical application. We treated the right ears of mice daily for 3 weeks with
vehicle or 2% (w/v) G-1 in DMSO, and observed a gradual increase pigmentation
compared to vehicle-treated controls over 3 weeks (Figure 2.4A). Melanin content was
increased 1.6-fold, a cosmetically significant change, and was consistent with the
magnitude of change seen in vitro (Figure 2.4B-C). Clinically apparent skin darkening on
mice increased over 2-3 weeks while pigment changes in culture were more rapid. It is
likely that the synthetic GPCR ligands are metabolized and/or distributed differently in
vivo then in in vitro culture, such that the effective local concentration of steroid in the in
vivo setting is relatively transient. Optimization of an ideal topical formulation and dosing
schedule will require additional study in the context of a human clinical trial.
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FIGURES

Figure 2.1. Estrogen and progesterone reciprocally regulate melanin synthesis. (A)
Melanin content of primary human melanocytes treated with estrogen (E2), compared to
vehicle-treated controls. (B) Fontana-Masson (melanin) staining of organotypic skin
treated with vehicle or estrogen. Relative melanin content is quantified below. (C) MITF
immunohistochemistry of organotypic skin treated with vehicle or estrogen. Melanocyte
population density is quantified below. (D) Melanin content of primary human
melanocytes treated with progesterone (P4), compared to vehicle. (E), Fontana-Masson
(melanin) staining of organotypic skin tissues treated with progesterone or vehicle.
Relative melanin content is quantified below. (F) MITF immunohistochemistry of
organotypic skin tissues treated with vehicle or progesterone. Melanocyte population
density is quantified below. n=3 biologic replicates for each experiment. Error bars
denote +/- s.d., *p<0.05, scale bar = 50 μm.
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Figure 2.1-figure supplement 1. Pregnancy-associated pigmentation changes. (A-C)
Clinical images of patients with melasma.
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Figure 2.1-figure supplement 2. Melanin production in melanocytes. (A) Schematic
representation of the classical melanin production pathway. (B) Melanin production in
response to aMSH. (C) Melanin production in response to estrogen (E2). (D) Melanin
production by melanocytes treated with vehicle, αMSH, or estrogen. (E) Melanin
production in response to ethinyl estradiol (EE2). (F) Melanin production in response to
progesterone (P4). (G) Melanin production in response to estrogen and progesterone
using iPS-derived female melanocytes. (H) Melanin production in response to estrogen
and progesterone using facial, aged-adult melanocytes. n=3 biologic replicates for each
experiment. Error bars denote +/- s.d., *p<0.05.
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Figure 2.1-figure supplement 3. Relative proliferative response to estrogen and
progesterone treatment. (A) Identical numbers of melanocytes from 3 donors were
seeded in parallel and treated with vehicle or estrogen; relative cell number after 5 days
was determined. (B) Identical numbers of melanocytes from 3 donors were seeded in
parallel and treated with vehicle or progesterone; relative cell number after 5 days was
determined. n=3 biologic replicates for each experiment. Error bars denote +/- s.d.,
*p<0.05.1
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Figure 2.2. Estrogen and progesterone access the classical melanin production pathway
through nonclassical receptors. (A) cAMP ELISA from estrogen-treated melanocytes (B)
Western blot demonstrating changes in classical melanin pathway regulators after a 16
hour estrogen treatment. (C) cAMP ELISA from progesterone-treated melanocytes. (D)
Western blot demonstrating changes in classical melanin pathway regulators after a 16
hour progesterone treatment. (E) Melanin assay from melanocytes treated with estrogen
and progesterone simultaneously. (F) Western blot for estrogen and progesterone
receptors in MCF7 cells and melanocytes. (G) Melanin content of melanocytes
transduced with control shRNA or shRNA targeting GPER. Cells were treated with either
vehicle or estrogen. (H) Melanin assay performed on melanocytes transduced with
control shRNA or shRNA targeting PAQR7. Cells were treated with either vehicle or
progesterone. n=3 biologic replicates for each experiment. Error bars denote +/- s.d.,
*p<0.05.
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Figure 2.2-figure supplement table 1. G protein-coupled receptors expressed in
melanocytes. RNA-seq data from primary human melanocytes(Flockhart et al., 2012)
was cross referenced with all known GPCRs(Alexander et al., 2013). Unique GPCR
genes with average RPKM values >1 are listed, by convention, RPKM values >1 indicate
genes that are expressed.
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Figure 2.2-figure supplement 1. Hormone receptors in melanocytes. (A) Relative gene
expression of classical hormone receptors in MCF7 cells and melanocytes, as
determined by qRT-PCR. Ct values were normalized to actin, and set relative to the
expression of androgen receptor (AR) in MCF7 cells. (B) Average RPKM values for
classical and nonclassical estrogen and progesterone receptor transcripts in human
melanocytes, by convention, RPKM values >1 indicate the gene is expressed. (C)
Expression of GPER and PAQR7 displayed as 1/Ct value. (D) Relative expression of
GPER and PAQR7 transcripts in melanocytes, fibroblasts, and keratinocytes, displayed
relative to the expression level in melanocytes. (E) qRT-PCR showing mRNA knockdown
efficiency of the two hairpins targeting GPER. (F) qRT-PCR showing mRNA knockdown
efficiency of the two hairpins targeting PAQR7. (G) Melanin content of melanocytes
transduced with LentiCRISPRV2 with guide RNA targeting GFP or GPER. Cells were
treated with either vehicle or estrogen. (H) Melanin content of melanocytes transduced
with LentiCRISPRV2 with guide RNA targeting GFP or PAQR7. Cells were treated with
either vehicle or progesterone. Error bars denote +/- s.d., *p<0.05.
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Figure 2.2-figure supplement 2. Progesterone signals through Gi in melanocytes. (A)
Melanin synthesis in response to Pertussis Toxin (PTX), progesterone (P4), or both. n=3
biologic replicates for each experiment. Error bars denote +/- s.d., *p<0.05
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Figure 2.3. GPER and PAQR7 signaling is sufficient to alter melanin production in
organotypic human tissue. (A) Organotypic skin treated with vehicle (left) or G-1 (right).
(B) Fontana-Masson (melanin) staining of organotypic skin treated with vehicle or G-1.
Quantification of melanin content is shown on the right. (C) MITF immunohistochemistry
of organotypic skin treated with vehicle or G-1. Quantification of melanocyte population
density is shown on the right. (D) Organotypic skin treated with vehicle (left) or CH2P4
(right). (E) Fontana-Masson (melanin) staining of organotypic skin treated with vehicle or
CH2P4. Quantification of melanin content is shown on the right. (F) MITF
immunohistochemistry of organotypic skin treated with vehicle or CH2P4. Quantification
of melanocyte population density is shown on the right. n=3 biologic replicates for each
experiment. Error bars denote +/- s.d., *p<0.05, scale bar = 50 μm.
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Figure 2.3-figure supplement 1. Melanin production is altered by sex steroid analogs
currently in clinical use. The effect of clinically relevant GPER agonists. (A) Melanin
production in response to tamoxifen (TMX). n=3 biologic replicates for each experiment.
Error bars denote +/- s.d., *p<0.05
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Figure 2.3-figure supplement 2. Targeting GPER with specific agonists and
antagonists. (A) Melanin production in response to G-1, a specific GPER agonist. (B)
Western blot demonstrating an increase in p-CREB after a 30 minute G-1 treatment. (C)
Western blot demonstrating an increase in MITF after a 16 hour G-1 treatment. (D)
Melanin assay performed on melanocytes lentivirally transduced with control shRNA or
shRNA targeting GPER. These cells were treated with either vehicle or G-1. (E) Melanin
production by melanocytes treated with vehicle, G-1, or estrogen, in the presence of
selective GPER antagonists G-15 or G-36. n=3 biologic replicates for each experiment.
Error bars denote +/- s.d., *p<0.05
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Figure 2.3-figure supplement 3. Targeting PAQR7 with specific agonists. (A) Melanin
production in response to CH2P4, a specific PAQR7 agonist. (B) Western blot
demonstrating a decrease in p-CREB after a 30 minute CH2P4 treatment. (C) Western
blot demonstrating a decrease in MITF after a 16 hour CH2P4 treatment. (D) Melanin
assay performed on melanocytes lentivirally transduced with control shRNA or shRNA
targeting PAQR7, cells were treated with either vehicle or CH2P4. n=3 biologic replicates
for each experiment. Error bars denote +/- s.d., *p<0.05.
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Figure 2.4. Topical GPER agonists increase pigmentation in vivo. (A) Mouse ear skin
treated for 3 weeks with vehicle only on the left ear, and 2% (w/v) G-1 on the right ear.
(B) Melanin assay on whole ear tissue that was treated with either vehicle or 2% G-1 for
3 weeks. (C) Fontana-Masson (melanin) staining of tissue sections from ears treated
with either vehicle or 2% G-1, quantification of staining on right. (D) Schematic model of
estrogen and progesterone signaling in melanocytes. n=3 biologic replicates for each
experiment. Error bars denote +/- s.d., *p<0.05, scale bar = 20 μm.
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Figure 2.4-figure supplement 1. NMR spectrometry of synthesized G-1. (A) H-NMR
spectrometry of synthesized G-1. 1H-NMR (500MHz, CDCl3) δ 7.70 (s, 1H), 7.61 (dd, J
= 5.0, 2.5 Hz, 1H), 7.09 (s, 1H), 7.01 (s, 1H), 6.61 (d, J = 8.5 Hz, 1H), 5.99 (d, J = 6.0
Hz, 2H), 5.93 (m, 1H), 5.67 (d, J = 4.5 Hz, 1H), 4.97 (d, J = 3.0 Hz, 1H), 4.12 (d, J = 9.0
Hz, 1H), 3.19 (q, J = 8.5 Hz, 1H), 2.54-2.48 (m, 4H), 1.84-1.79 (m, 1H). (B) 13C-NMR
spectrometry of G-1. 13C-NMR (125MHz, CDCl3) δ 196.5, 150.0, 147.5, 147.4, 133.8,
133.5, 130.4, 130.0, 128.5, 127.6, 125.0, 115.1, 112.9, 112.8, 107.6, 101.8, 56.1, 45.3,
42.0, 31.3, 26.0.
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DISCUSSION
Safe and effective approaches for modulating skin melanocyte function for
therapeutic benefit are lacking, largely because the factors normally regulating
melanocyte homeostasis are complex and incompletely deciphered. Defining these
mechanisms is important however, as myriad genetic and acquired conditions including
common afflictions such as acne, eczema, vitiligo, ultraviolet (UV) radiation exposure,
traumatic injury, and pregnancy are associated with alterations in skin pigmentation that
can be extensive and long-lasting (James et al., 2011). Another population that could
potentially benefit from modulating skin pigment are people with naturally light skin,
especially those with red hair, who have a markedly decreased ability to synthesize UVprotective brown eumelanin as a result of inactivating mutations in MC1R (Valverde et
al., 1995). This large population is especially susceptible to photodamage, sunburns,
and has an increased lifetime risk of keratinocyte and melanocyte-derived skin cancers
(Han et al., 2006). There is currently no available therapeutic that promotes protective
eumelanin pigment production. However, the specific activation of GPER alternatively
activates cAMP signaling, bypassing MC1R, to stimulate melanin synthesis, and could
therefore be especially useful in this sun-vulnerable population.

Selective GPER

activation in skin could potentially be a safe alternative to intentional UV radiation
exposure (via natural sunlight or tanning beds) for individuals seeking what they perceive
as an aesthetically desirable tan. The only method currently available to increase skin
melanin is UV exposure. While effective at darkening skin, the requisite DNA damage
promotes premature aging, wrinkles, and skin cancer.
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Commonly utilized approaches for decreasing skin melanin are also often unsafe,
and involve application of toxic mercury or arsenic compounds, especially common in
India, China, Japan, and Korea, but also encountered in the U.S., and recently
highlighted in a report from the California Department of Public Health (Report #14-046,
2014), or hydroquinone, a tyrosinase inhibitor, which has been banned in Europe
because of concerns regarding its possible association with cancer (McGregor, 2007).
Our findings describe small molecule sex steroid analogs, without these toxicities, that
modulate pigment production (Figure 2.4D).
Therapeutic use of GPER or PAQR7 agonists/antagonists could potentially have
effects on cells other than epidermal melanocytes. While topical delivery of such agents
would likely avoid off target effects in distant tissues, there exits the theoretical possibility
of off-target effects within the skin. However, we did not note any significant
abnormalities in the epidermis from our in vitro or in vivo skin tissues treated with the sex
steroids.
GPER and PAQR7 have been identified only relatively recently, but are
expressed in several tissues, and may mediate at least some of the estrogen and
progesterone effects that cannot be attributed to the classical nuclear hormone
receptors. GPER has been identified in the reproductive, nervous, cardiovascular, renal,
pancreas, and immune systems (Prossnitz and Barton, 2011). In immune cells, GPER
expression on T cells has been shown to play a role in 17β-estradiol-induced thymic
atrophy and autoimmune encephalomyelitis. PAQR7 is expressed in the reproductive
and nervous systems (Tokumoto et al., 2016), and in murine macrophages (Lu et al.,
2015) and in human T cells (Dosiou et al., 2008), although the functional role of PAQR7
in those tissues remains relatively unclear. Given that the increased systemic estrogen
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and progesterone associated with pregnancy does not typically result in skin cancer or
significant pathology in other tissues, we think it likely that the specific GPER and
PAQR7 agonists will be well tolerated. Nonetheless, formal toxicity studies and careful
evaluation of human skin treated in clinical trials will be important.
The finding that PAQR7 works through inhibitory Gi subunits is especially
interesting, as it is the first example of a melanocyte cellular signaling cascade that
actively represses melanin synthesis at the level of G-protein signaling, as opposed to
classically defined pigment control mechanisms that modulate the strength of the
stimulatory MC1R signal. In many animal systems, the Agouti protein decreases pigment
production via physically binding to MC1R and inhibiting αMSH stimulation (Ollmann et
al., 1998), rather than through an actively suppressive mechanism.
Our finding that normal primary melanocytes lack nuclear ER or PR contradicts a
prior report (Im et al., 2002). This group performed immunohistochemistry and RT-PCR
to support the claim that nuclear estrogen receptors are expressed in melanocytes, but
in our view, the data presented in that work is not especially convincing, and there is no
evidence in that work that nuclear hormone signaling drives changes in melanin
synthesis. Another group demonstrated that melanocyte protein extracts have the ability
to bind radioactive estrogen, but that work did not identify the specific protein(s)
responsible for the binding activity (Jee et al., 1994). We do not exclude the possibility
that in some tissue settings, including neoplastic lesions and possibly hair follicles,
melanocytes express nuclear ER/PR. Still, as there is no known direct signaling pathway
linking nuclear sex hormone receptors to the melanin synthesis machinery, it is most
likely that the major effects of estrogen and progesterone on pigment production are
mediated through the Gs and Gi coupled GPCRs identified in our current work.
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We have shown that signaling through GPCRs other than MC1R directly affects
melanin production. While surveying all the 7-pass transmembrane proteins expressed
in melanocytes, we noted expression of several additional receptors that may also
influence melanin production. These include histamine (Lassalle et al., 2003; Yoshida et
al., 2000) and leukotriene receptors, which in other contexts are known to signal through
Gs and Gi subunits (Arcemisbehere et al., 2010; Mondillo et al., 2005). Future functional
analysis of these and other GPCRs in melanocytes may elucidate the mechanisms
responsible for the pigmentation changes that frequently accompany many skin
diseases associated with inflammation. These studies may identify additional “drugable”
and therapeutically useful receptors in melanocytes, and will help advance an
understanding of how cumulative GPCR signaling is integrated to regulate melanin
production in human skin.
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METHODS
Melanocyte Culture
Primary melanocytes were extracted from fresh discarded human foreskin and surgical
specimens as described previously described with some modifications detailed as
follows. After overnight incubation in Dispase, the epidermis was separated from the
dermis and treated with trypsin for 10 minutes.

Cells were pelleted and plated on

selective MC Medium 254 (Invitrogen) with Human Melanocyte Growth Supplement, and
1% penicillin and streptomycin. Lightly pigmented primary melanocytes were utilized for
experiments assaying estrogen and GPER agonist effects, and heavily pigmented
primary melanocytes were utilized for experiments assaying progesterone and PAQR7
agonist effects in melanin production. Female iPS-derived human melanocytes were a
gift from Meenhard Herlyn (Wistar Institute, Philadelphia, PA, USA). Progesterone
(P8783), 17β-Estradiol (E8875), and αMSH (M4135) were purchased from SigmaAldrich. G-1 (10008933), G-15 (14673) and G-36 (14397) were purchased from Cayman
Chemical. CH2P4 (2085) was purchased from Axon Medchem. Pertussis toxin was
purchased from R&D systems (3097). These compounds were diluted to working stock
solutions in Medium 254.
Melanin Assay
2 x 105 melanocytes were seeded uniformly on 6-well tissue culture plates. Cells were
treated with vehicle controls, sex steroids, hormone derivatives, or pertussis toxin for 4
days. Cells were then trypsinized, counted, and spun at 300g for 5 minutes. The
resulting cell pellet was solubilized in 120μL of 1M NaOH, and boiled for 5 minutes. The
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optical density of the resulting solution was read at 450 nm using an EMax microplate
reader (Molecular Devices). The absorbance was normalized to the number of cells in
each sample, and relative amounts of melanin were set based on vehicle treated
controls. For tissue melanin assays, tissue was weighed prior to boiling in 1M NaOH for
20 minutes. Samples were spun down to eliminate insoluble materials, and then the
optical density of the sample was measured as previously described and normalized to
the weight of tissue.
Preparation of 3-D Organotypic Skin Cultures
Organotypic skin grafts containing MCs were established using modifications to
previously detailed methods(Chudnovsky et al., 2005; Ridky et al., 2010).

The

Keratinocyte Growth Media (KGM) used for keratinocyte-only skin grafts was replaced
with modified Melanocyte Xenograft Seeding Media (MXSM). MXSM is a 1:1 mixture of
KGM, lacking cholera toxin, and Keratinocyte Media 50/50 (Gibco) containing 2% FBS,
1.2 mM calcium chloride, 100 nM Et-3 (endothelin 3), 10 ng/mL rhSCF (recombinant
human stem cell factor), and 4.5 ng/mL r-basic FGF (recombinant basic fibroblast growth
factor). 1.5 x 105 melanocytes and 5.0 x 105 keratinocytes were suspended in 80 μL
MXSM, seeded onto the dermis, and incubated at 37 ˚C for 8 days at the air-liquid
interface.
Topical G-1 Treatment
2% (w/v) G-1 was prepared in DMSO, 20 μL of this solution was applied daily to the right
ear, with vehicle only applied to the left ear, of 4-week-old C57BL/6 mice. These studies
were preformed without inclusion/exclusion criteria, randomization, or blinding. Based on
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a two-fold anticipated effect, we preformed this experiment with 3 biological replicates.
All procedures were performed in accordance with IACUC-approved protocols at the
University of Pennsylvania.
Western Blot Analyses and Antibodies.
Adherent cells were treated with 1 mM doses of E2 and P4 overnight, washed once with
DPBS, and lysed with 1% NP-40 buffer (150 mM NaCl, 50 mM Tris, pH 7.5, 1 mM
EDTA, and 1% NP-40) containing 1X protease inhibitors (Roche) and 1X phosphatase
inhibitors (Roche). Lysates were quantified (Bradford assay), normalized, reduced,
denatured (95 ˚C) and resolved by SDS gel electrophoresis on 4-15% Tris/Glycine gels
(Bio-Rad). Resolved protein was transferred to PVDF membranes (Millipore) using a
Semi-Dry Transfer Cell (Bio-Rad), blocked in 5% BSA in TBS-T and probed with primary
antibodies recognizing MITF (Cell Signaling Technology, #12590, 1:1000), p-CREB (Cell
Signaling Technology, #9198, 1:1000), CREB (Cell Signaling Technology, #9104,
1:1000), and β-Actin (Cell Signaling Technology, #3700, 1:4000). After incubation with
the appropriate secondary antibody, proteins were detected using either Luminata
Crescendo Western HRP Substrate (Millipore) or ECL Western Blotting Analysis System
(GE Healthcare).
cAMP ELISA
cAMP ELISA was performed on primary human melanocytes using the Cyclic AMP XP
Assay Kit (Cell Signaling Technology, #4339) following manufacturer instructions.
Melanin Staining
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Formalin-fixed paraffin embedded tissue was sectioned at 5 mM and collected on
superfrost

plus

slides

melanin(Masson, 1928).

(Fisher),

and

subjected

to

Fontana-Masson

stain

for

Briefly, sections were deparaffinized, rehydrated, and

incubated in the following solutions:

2.5% aqueous silver nitrate for 10 min, 0.1%

aqueous gold chloride for 15 min, and 5% aqueous sodium thiosulfate for 5 min.
Distilled deionized water was used for rinsing and incubations were done at room
temperature except for silver nitrate at 60°C.

Slides were counterstained with 0.1%

nuclear fast red Kernechtrot for 5 min, dehydrated, cleared, and coverslipped using
MM24 mounting media (Leica). All staining reagents were from Polyscientific R and D
Corporation.
Immunohistochemistry
Formalin fixed paraffin embedded (FFPE) human skin tissue sections from organotypic
tissue was stained for MITF protein expression using a primary antibody to MITF (Leica
Biosystems, NCL-L-MITF, 1:15). Staining was performed following the manufacturer
protocol for high temperature antigen unmasking technique for immunohistochemical
demonstration on paraffin sections.
Quantification of Melanin Staining
Tissue sections from organotypic culture were stained using methods described above.
Quantification was performed according to Billings et al(Billings et al., 2015). Briefly, 20X
photomicrograph images of representative tissue sections were taken using the Zeiss
Axiophot microscope. Tiff files of the images were saved and transferred to Adobe
Photoshop where pixels corresponding to Fontana-Masson staining and epidermal
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counter stain were selected using the color selection tool. Images corresponding to the
single specific color were then analyzed using FIJI (Image J) to determine the number of
pixels in each sample. The numbers of pixels representing Fontana-Masson staining
were normalized to the total amount epidermal counter staining. Final ratios FontanaMasson staining in the epidermis relative to amount of staining in vehicle treated
controls.
Quantitative RT/PCR
mRNA was extracted from melanocytes according to the RNeasy Mini Kit

protocol

(Qiagen), and reverse transcribed to cDNA using the High Capacity RNA-to cDNA kit
(Applied Biosystems). Quantitative PCR of the resulting cDNA was carried out using
Power SYBR Green Master Mix (Applied Biosystems) and gene-specific primers, in
triplicate, on a ViiA 7 Real-Time PCR System (Life Technologies). The following primers
were used for detection; B-Actin forward: 5’-CAT GTA CGT TGC TAT CCA GGC-3’; BActin reverse: 5’-CTCCTTAATGTCACGCACGAT -3’; ER-A forward: 5’- AAA GGT GGG
ATA CGA AAA GAC C -3’; ER-A reverse: 5’-AGC ATC CAA CAA GGC ACT GA-3’; ERB forward: 5’ – GGC TGC GAG AAA TAA CTG CC -3’; ER-B reverse: 5’-AAT GCG GAC
ACG TGC TTT TC-3’; PGR forward: 5’- AGG TCT ACC CGC CCT ATC TC -3’; PGR
reverse: 5’-AGT AGT TGT GCT GCC CTT CC -3’; AR forward: 5’- GTG CTG TAC AGG
AGC CGA AG -3’; AR reverse: 5’- GTC AGT CCT ACC AGG CAC TT -3’; GPER
forward: 5’-ACA GAG GGA AAA CGA CAC CT -3’; GPER reverse: 5’- AAT TTT CAC
TCG CCG CTT CG -3’; PAQR7 forward: 5’- GTG CAC TTT TAT ACC GTC TGC TT -3’;
PAQR7 reverse: 5’- CCT GGG CAG GGA GCT AAG AT -3’. Relative expression was
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determined using the 2-[delta][delta] Ct method followed by normalization to the AR
receptor transcript levels in MCF7 cells.
Lentiviral Vectors
The following shRNAs were expressed from the GIPZ vector and are available through
Open

Biosystems.

shPAQR7.4

shPAR7.3

(V3LHS_364598,

(V2LHS_132008,

(V3LHS_364596,

TGTGGTAGAGAAGAGCTGG),

AGAAGTGTGCCAAGGCACT),

TCCTTCTCCTCTTTAACTC),

shGPER.3

shGPER.1

(V3LHS_390319,

TGATGAAGTACAGGTCGGG). Guide RNAs were designed using software tools
developed by the Zhang Lab and provided on the website http://www.genomeengineering.org/ (Hsu et al., 2013). Guide RNAs were subsequently cloned into
lentiCRISPRv2 (Addgene # 52961) according to the accompanying protocol (Sanjana et
al., 2014). Guide RNA sequences are as follows: lentiCRISPR GFP 5’ GAA GTT CGA
GGG CGA CAC CC 3’; lentiCRISPR GPER.1 5’ ACAGGCCGATCACGTACTGC 3’;
lentiCRISPR GPER.2 5’ GAGCACCAGCAGTACGTGAT 3’; lentiCRISPR PAQR7.1 5’
CGTACATCTATGCGGGCTAC

3’;

lentiCRISPR

PAQR7.5

5’

CGTGCGGAAATAGAAGCGCC 3’
Synthesis of G-1
G-1

(±)

1-(4-(6-bromobenzo[d][1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-

cyclopenta[c]quinolin-8-yl)ethan- 1-one was prepared by the method of Baudelle, et.
al(Baudelle

et

al.,

1998)

6-bromopiperonal

(1.110

g,

4.85

mmol)

and

4-

aminoacetophenone (656 mg, 4.85 mmol) were dissolved in anhydrous acetonitrile (16.2
mL, 0.3M) and allowed to stir at 25oC under argon. After approximately 1.5 h,
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trifluoroacetic acid (350 μL, 4.61 mmol) was added and the reaction was allowed to stir
at 25oC for 45 min. Freshly prepared cyclopentadiene (1.63 mL, 19.4 mmol) was added
dropwise to the reaction mixture. After 2 h at 25oC the reaction mixture was concentrated
in vacuo. The crude product was purified by silica gel chromatography using 30% EtOAc
in hexanes as eluent to provide racemic 1-(4-(6-bromobenzo[d][1,3]dioxol-5-yl)3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)ethan-1-one (1.05 g, 53 %). The G-1
was >95% pure as determined by high pressure liquid chromatography analysis. 1H and
13C NMR were identical to the data reported by Burai, et. al(Burai et al., 2010).
Statistics
* denotes a P-value of less than 0.05 in an unpaired, two-tailed Students T-Test,
assuming a normal distribution and equal variance. Due to the anticipated effect size of a
two-fold change, experiments were performed with 3 biological replicates.
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CHAPTER 3: NONCLASSICAL ESTROGEN SIGNALING INHIBITS MELANOMA
AND IMPROVES RESPONSE TO IMMUNE CHECKPOINT BLOCKADE

Parts of this chapter have been previously published in:
Natale, C. A., Li, J., Zhang, J., Dahal, A., Dentchev, T., Stanger, B. Z., & Ridky, T. W.
(2018). Activation of G protein-coupled estrogen receptor signaling inhibits melanoma
and improves response to immune checkpoint blockade. eLife, 7, e31770.
http://doi.org/10.7554/eLife.31770
OVERVIEW
Female sex and history of prior pregnancies are associated with favorable
melanoma outcomes. Here we show that much of the melanoma protective effect likely
results from estrogen signaling through the G protein-coupled estrogen receptor (GPER)
on melanocytes. Selective GPER activation in primary melanocytes and melanoma cells
induced long-term changes that maintained a more differentiated cell state as defined by
increased expression of well-established melanocyte differentiation antigens, increased
pigment production, decreased proliferative capacity, and decreased expression of the
oncodriver and stem cell marker c-Myc. GPER signaling also rendered melanoma cells
more vulnerable to immunotherapy. Systemically delivered GPER agonist was well
tolerated, and cooperated with immune checkpoint blockade in melanoma-bearing mice
to dramatically extend survival, with up to half of mice clearing their tumor. Complete
responses were associated with immune memory that protected against tumor
rechallenge. GPER may be a useful, pharmacologically accessible target for melanoma.
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INTRODUCTION
Melanoma is the most deadly form of skin cancer and incidence is rising
worldwide. Despite recent advancements in immunotherapies, the majority of patients
with metastatic melanoma will still succumb to their disease (Hamid et al., 2013; Ribas et
al., 2016). There is an acute need for new therapeutic strategies that augment the
efficacy of standard-of-care immune checkpoint inhibitors. Clues to potential new
therapeutic targets for melanoma may be found in 50 year old observations (White,
1959), validated in recent studies, that female sex, history of multiple pregnancies, and
decreased maternal age at first birth are associated with decreased melanoma incidence
and favorable prognosis (Bannister-Tyrrell et al., 2014; Gandini et al., 2011; Hersey et
al., 1977; Joosse et al., 2013; Karagas et al., 2006; Magnus, 1977). Although the
mechanism of this protective effect is unknown, the clinical association suggests that sex
hormone signaling is involved. We hypothesized that understanding the relevant
hormones, receptors, and downstream signaling events activated in melanocytes by
pregnancy-associated sex steroids would help define the mechanism of the female
melanoma protective effects, and suggest new therapeutic opportunities.
In melanocytes, facultative pigmentation and differentiation is primarily regulated
by melanocortin receptor 1 (MC1R), which is a Gs-coupled G protein-coupled receptor
(GPCR). MC1R activation results in the stimulation of adenylate cyclase, which produces
cyclic adenosine monophosphate (cAMP). cAMP activates protein kinase A (PKA),
which phosphorylates and activates the cAMP response element-binding protein
(CREB). CREB is a component of a transcription factor complex that drives transcription
of microphthalmia-associated transcription factor (MITF), which is known as the master
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regulator of melanocyte differentiation (D'Orazio and Fisher, 2011). MITF directs
transcription of melanocyte specific genes required for melanin synthesis including
tyrosinase. In previous studies we determined that estrogen, which is higher in females,
especially during pregnancy, acts directly on skin melanocytes to increase both pigment
production and melanocyte differentiation (Natale et al., 2016). These estrogen effects
are mediated entirely through a GPCR named G-protein coupled estrogen receptor
(GPER). GPER activates signaling pathways that are completely distinct from classical
estrogen receptors (Filardo et al., 2002). Although there are no approved drugs that
specifically target GPER, we determined that GPER is activated in both female and male
normal melanocytes by estrogen, as well as by a selective agonist (G-1) that activates
GPER signaling without affecting the activity of classical estrogen receptors (ERα/β)
(Bologa et al., 2006). An independent laboratory subsequently validated these results
(Sun et al., 2017). Here we show that GPER activation in melanoma induces a
constellation of long-lasting phenotypic changes that inhibit tumor growth, and also
render tumor cells more susceptible to clearance by native immune cells, which
increases the clinical efficacy immune checkpoint blockade. Selective GPER agonists
may represent a new class of anti-cancer therapeutics.
RESULTS
To test whether pregnancy affects melanoma development, we used geneticallydefined human melanoma (heMel) xenografts (Chudnovsky et al., 2005; McNeal et al.,
2015). In this tissue model, primary human melanocytes were engineered with
lentiviruses to express mutant oncoproteins commonly associated with spontaneous
human melanoma (McNeal et al., 2015) including BRAFV600E (doxycycline-inducible),
69

dominant-negative p53R248W, active CDK4R24C and hTERT (Figure 3.1-figure supplement
1A). The oncogene expressing melanocytes were combined with primary human
keratinocytes and native human dermis to construct functional 3-dimensional human skin
tissues that were grafted into the orthotopic location on the backs of female mice (Figure
3.1-figure supplement 1B). After grafts healed, mice were randomized and separated
into nonbreeding or breeding groups (Figure 3.1A). Doxycycline chow was then provided
to induce the BRAFV600E oncogene in all animals. After 15 weeks and 3 consecutive
pregnancies in the breeding group (or no pregnancies in the nonbreeding group), human
tissues were harvested and analyzed histologically. Grafts from the nonbreeding group
developed into melanocytic neoplasms with hallmark features of human melanoma
including large, mitotically active melanocytic nests with cellular atypia (Figure 3.1B-D
and Figure 3.1-figure supplement 1C). In contrast, tissues from the breeding group were
relatively unremarkable, and contained primarily quiescent, single, non-proliferating
melanocytes that were confined to the basal epidermal layer. These results show that
repeated pregnancies inhibit the growth of BRAF-driven human melanocytic neoplasia.
The primary role of a fully differentiated epidermal melanocyte is to produce
melanin pigment that protects the skin from ultraviolent radiation (D'Orazio and Fisher,
2011; D'Orazio et al., 2006; Lin and Fisher, 2007). As with most cell types, melanocyte
differentiation and proliferation are inversely correlated, and melanocytes in normal skin
rarely proliferate outside of cycling hair follicles (Jimbow et al., 1975; Rabbani et al.,
2011). Melanoma tissue is generally less differentiated than normal melanocytes or
benign nevi. In our xenograft studies, pregnancy was associated the relative lack of
proliferating melanocytes and corresponding increase in epidermal melanin, suggesting
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that these melanocytes are relatively more differentiated. Although the nonbreeding
group, which developed melanomas, had significantly more melanocytes in the grafted
skin than the breeding group, melanin abundance within the surrounding epidermal
keratinocytes was reduced (Figure 3.1E). These data suggest that pregnancy inhibits
melanoma development and induces melanocyte pigment production.
To test whether pregnancy-associated hormones induce long-lasting changes in
melanocytes that could account for the melanoma survival benefit observed in some
studies of women who experienced pregnancy decades earlier, we transiently exposed
primary human melanocytes to estrogen or progesterone. Continuous estrogen
exposure drove increases in melanin production, while progesterone had opposite
effects (Figure 3.2A). After hormone withdrawal, progesterone treated cells quickly
returned to their baseline level of melanin production. In contrast, estrogen treated cells
stably produced more melanin through continual cell divisions over the subsequent 50
days. A subset of cells that were exposed to transient estrogen were subsequently
treated with progesterone. This reversed the estrogen effects, and melanin production
decreased to the sub-baseline level seen upon initial progesterone treatment.
Remarkably, after progesterone withdrawal, these cells fully returned back to the
heightened level of melanin production induced by the initial estrogen exposure (Figure
3.2A). In addition to increased melanin production, transient estrogen exposure was
associated with stable increases in well-established melanocyte differentiation proteins
including tyrosinase (TYR), p-CREB and MC1R (Figure 3.2B). These results indicate
that estrogen signaling, even transiently, induces a durable, long-lasting effects in
melanocytes associated with markers of a more fully differentiated cell state.
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To determine whether estrogen similarly increased melanin production and
expression of differentiation proteins in melanoma cells, we treated mouse (B16F10) or
several human melanoma cells (WM46, WM51, WM3702) with either estrogen, or the
specific GPER agonist G-1. Consistent with changes observed in heMel cells in vivo,
estrogen or G-1 decreased melanoma cell proliferation and increased melanin
production, independent of the specific oncodrivers (BRAFV600E or NRasQ61L) (Figure 3.2figure supplement 1A-D).

G-1 treatment resulted in a dose-dependent inhibition of

melanoma proliferation, saturating at an optimal dose of 500nM (Figure 3.2-figure
supplement 1E-F). The effects of G-1 are lost completely when GPER is genetically
depleted (Figure 3.2-figure supplement 1H-J). These data, coupled with the finding that
G-1, which is a specific agonist of GPER that has no activity on classical estrogen
receptors, indicate that the entirely of the estrogen and G-1 effects in melanoma cells
are mediated through GPER. Consistent with this, we did not detect expression of ERα
in several melanoma cell lines (Figure 3.2-figure supplement 1G). In previous work, we
demonstrated that GPER was also the sole mediator of estrogen and G-1 effects in
normal primary human melanocytes (Natale et al., 2016).
To test whether transient GPER signaling induces a persistent state in melanoma
cells that affects subsequent tumor growth in vivo, we treated melanoma cells with
estrogen, G-1, or vehicle in vitro, and subsequently injected equal numbers of treated
cells into host mice (Figure 3.2C). Pretreatment with estrogen or G-1 markedly reduced
subsequent tumor size (Figure 3.2D-E), indicating that transient GPER activation has
durable, long-lasting effects on melanoma cells that limit tumor growth in vivo.
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Amplification of c-Myc – a transcription factor that antagonizes differentiation and
promotes proliferation, survival, and escape from immune surveillance – is one of the
most common genetic alterations in human cancers, including melanoma (Gabay et al.,
2014; Schlagbauer-Wadl et al., 1999). We found that GPER signaling in melanoma cells
stably depleted c-Myc protein, and induced a relative growth arrest. This was associated
with persistent hypophosphorylation of RB, increased expression of melanocyte
differentiation proteins including TYR, MITF, and MC1R, increased expression of human
leukocyte antigen (HLA), and reduced expression of programmed cell death ligand-1
(PD-L1) (Figure 3.3A-D and Figure 3.2-figure supplement 1E-F). Genetic knockdown of
GPER eliminated G-1 effects on p-RB, c-Myc, and proliferation (Figure 3.2-figure
supplement 1H-J). To verify this finding indicating that G-1 effects in melanoma are
mediated entirely through GPER, we utilized a selective GPER antagonist, G-36 (Dennis
et al., 2011), that specifically inhibits GPER. In melanoma cells, a two-fold molar excess
of G-36 completely blocked G-1 effects (Figure 3.3F). c-Myc loss is a major mediator of
the anti-proliferative effects of GPER signaling, as melanoma cells engineered to
maintain c-Myc protein in the face of GPER activation were resistant to G-1 (Figure
3.3E). c-Myc loss following GPER activation was rapid (Figure 3.3G) and PKA
dependent (Figure 3.3H), suggesting that canonical stimulatory G protein-coupled
receptor signaling destabilized c-Myc protein. Consistent with this, c-Myc loss after
GPER activation was proteasome dependent (Figure 3.3I), and c-Myc protein half-life
was markedly shortened (Figure 3.3J). Together, these data indicate that GPER
activation regulates c-Myc through protein degradation. A recent report showed that
melanomas arising during pregnancy are associated with higher GPER protein within
tumor sections, suggesting that hormonal factors may upregulate GPER expression
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(Fabian et al., 2017). Consistent with these clinical data, G-1 induced a dose-dependent
increase in GPER expression in melanoma cells (Figure 3.3-figure supplement 1A). To
determine whether pathways downstream of GPER activated in vitro were similarly
activated in vivo, we treated WM46 tumor-bearing mice with vehicle or G-1, and
observed increased p-CREB and GPER, and decreased c-Myc in tumor sections (Figure
3.3-figure supplement 1B-C).
Beyond its role in stimulating proliferation and inhibiting differentiation, c-Myc was
recently shown to contribute to tumor aggressiveness by promoting expression of
multiple inhibitory immune checkpoint regulators on tumor cells including PD-L1 (Casey
et al., 2016; Kim et al., 2017). Consistent with this, pharmacologic GPER activation in
melanoma cells resulted in parallel decreases in both c-Myc and PD-L1 (Figure 3.4A-C).
This PD-L1 depletion was depend on c-Myc loss, as PD-L1 was preserved in cancer
cells engineered to maintain normal c-Myc levels in the presence of GPER agonist
(Figure 3.3E). Given that GPER signaling induced stable changes in tumor cells that
antagonized tumor proliferation and decreased tumor cell expression of immune
suppressive proteins, we next questioned whether GPER activation potentiates the antitumor activity of immune checkpoint blockade inhibitors which are currently the standard
of care for advanced melanoma in people (Hamid et al., 2013; Ribas et al., 2016).
To determine whether tumor cell intrinsic GPER signaling influences melanoma
vulnerability to immune checkpoint therapy, we took advantage of the fact that GPER
effects are long-lasting. We used G-1 to activate GPER in murine B16F10 melanoma
cells in vitro (Figure 3.4D). We then injected equal numbers of vehicle or G-1 treated
tumor cells into syngeneic C57BL/6 mice, and treated the animals with either anti74

programmed cell death 1 (αPD-1) antibody or isotype antibody control. Consistent with
the premise that GPER signaling has long-lasting effects on melanoma cells, G-1
pretreatment alone inhibited subsequent tumor growth in mice and extended survival
compared to controls. αPD-1 antibody monotherapy in animals injected with vehicle
treated B16F10 cells also similarly prolonged survival. However, combination of G-1
pretreatment with αPD-1 antibody extended survival beyond that seen with either agent
alone, indicating that GPER activity in tumor cells induced persistent changes in the
tumor sufficient to improve the anti-tumor activity of systemically administered aPD-1
therapy (Figure 3.4E-F). To further demonstrate that GPER activation has tumor-cell
intrinsic activity in vivo, we treated YUMM1.7-bearing immunocompromised mice with G1 (Figure 3.4-figure supplement 1A). Treatment with G-1 slowed tumor growth and
extended survival (Figure 3.4-figure supplement 1B-C). Together, these data suggest
that GPER signaling likely inhibits melanoma progression in a tumor cell intrinsic
manner.
To determine whether G-1 may have therapeutic utility as a systemically
delivered agent for established melanoma, with or without immune checkpoint inhibitors,
mice harboring syngeneic melanoma initiated from naïve, untreated B16F10 cells were
treated with subcutaneous G-1, αPD-1 antibody, or both, and survival compared to
matched mice treated with vehicle and isotype antibody controls (Figure 3.5A). G-1,
which lacks systemic toxicities associated with estrogen (Wang et al., 2009), was well
tolerated in mice and G-1 monotherapy extended survival to the same extent as αPD-1.
Treatment with both αPD-1 and G-1 extended survival dramatically, indicating a marked
combinatorial benefit (Figure 3.5B-C). Although B16F10 melanoma is the most
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commonly used model for melanoma immunology studies, and experimental results
have largely translated to humans (Benci et al., 2016; Twyman-Saint Victor et al., 2015),
B16F10 lacks the BRaf or NRas oncodriver mutations present in most human
melanomas (Cancer Genome Atlas, 2015; Shain et al., 2015). To test whether GPER
signaling has similar anti-melanoma activity in a potentially more medically relevant
model, we used genetically-defined melanoma cells from the newly-available Yale
University Mouse Melanoma collection (YUMM). This resource contains melanoma lines
generated

from

established

genetically

engineered

mouse

models

that

were

backcrossed onto C57BL/6 backgrounds specifically to facilitate immunology studies
(Meeth et al., 2016). We injected YUMM 1.7 cells (BRafV600E/wt Pten-/- Cdkn2-/-) into
C57BL/6 mice, and initiated G-1 treatment with and without αPD-1 after tumors reached
3-4 mm in diameter (Figure 3.5D). Similar to results observed with B16F10 melanoma,
G-1 or αPD-1 monotherapy significantly extended survival, while combination treatment
dramatically extended survival further, including long-term survivors (Figure 3.5E-F).
These results indicate that GPER anti-tumor activity is independent of tumor oncodriver.
Consistent with the hypothesis that GPER activation changes the nature of immune
infiltration, G-1 treatment in melanoma-bearing mice increased several immune cell
subsets, including T cells and NK cells, suggesting a more robust inflammatory response
(Figure 3.5-figure supplement 1A-C). We also observed an increase of CD8+ T cells in
the central regions of tumors treated with G-1 (Figure 3.5-figure supplement 1D).
As the efficacy of immunotherapy generally decreases as the size of the tumor
burden increases (Huang et al., 2017), we next questioned whether initiating treatment
of mice with YUMM 1.7 melanoma at an earlier time point would increase the number of
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complete responders with long-term survival. When we began the G-1/αPD-1 regimen 4
days after introduction of YUMM 1.7 melanoma cells, the percentage of complete
responders increased from 20% to 50%, with no evidence of tumor at day 100 (Figure
3.6A-B). We considered these mice “cleared”. Cleared mice were then rechallenged with
YUMM 1.7 melanoma, and we compared tumor growth and survival to age/litter
matched, naïve mice injected with the same number of YUMM 1.7 cells. While the
control mice grew large tumors and succumbed to disease, all of the previously cleared
mice lived longer, and 80% remained tumor free without any additional treatment (Figure
3.6C-F). To test further that the cleared mice have immunity against an antigen that is
not specific to the YUMM1.7 line, we rechallenged the surviving mice again B16F10
melanoma. B16F10 is more aggressive than YUMM1.7 and harbors distinct oncogenic
mutations, and there was a significant delay in tumor growth in the YUMM1.7 cleared
mice, with 20% of mice remaining tumor free without additional treatment (Figure 3.6figure supplement 1A-B). These results indicate that tumor clearance with G-1/αPD-1
combination therapy is associated with the formation of generalized anti-melanoma
immune memory.
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FIGURES

Figure 3.1. Multiple pregnancies inhibit melanomagenesis. (A) Experimental timeline of
genetically-defined human xenograft melanoma on SCID mice, n = 5 per group. (B)
Histologic characterization of representative orthotopic skin and resulting tumors,
including hematoxylin and eosin (H/E), melanocyte and proliferation markers MITF,
Ki67/MART, and Fontana Masson (Melanin). Scale bars = 100μM. C-E, Quantification of
epidermal MITF staining (C), Ki67 proliferation index (D) and melanin staining in
epidermal keratinocytes (E), * denotes significance by the Mann-Whitney test.
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Figure 3.1- figure supplement 1. Multiple pregnancies inhibit melanomagenesis. (A)
Western blot validating the transduction of normal human melanocytes with doxycycline
inducible BRAF(V600E), dominant-negative p53(R248W), active CDK4(R24C) and
hTERT. (B) Representative photo of a SCID mouse with a human engineered melanoma
xenograft. (C) MITF immunohistochemistry across all non-breeding and breeding mice, *
denotes replicates shown in Figure 3.1B. Scale bars = 100μM
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Figure 3.2. GPER signaling drives stable differentiation in normal human melanocytes
and in melanoma. (A) Long-term melanin assay in which normal human melanocytes
were transiently treated with progesterone (P4), or estrogen (E2). Subsets of these
groups (Red) were treated with an additional transient pulse of P4 at Day 27. Error bars
equal the standard deviation of the samples. (B) Western blot of melanocyte
differentiation markers after a transient, 4-day treatment with either vehicle or estrogen,
followed by an 8 day withdraw period. (C) Experimental timeline of estrogen or GPER
agonist (G-1) pre-treatment of mouse and human melanoma cells, n=5 per group. (D)
Relative tumor weights of mouse and human melanomas pre-treated with estrogen, *
denotes significance by the Mann-Whitney test. (E) Relative tumor weights of mouse and
human melanomas pre-treated with G-1, * denotes significance by the Mann-Whitney
test.
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Figure 3.2-figure supplement 1. GPER signaling slows proliferation and drives
differentiation in mouse and human melanoma. (A) 5 day proliferation assay of B16F10,
WM46 (BRAFV600E), WM51 (BRAFV600E), and WM3702 (NRASQ61L) cells treated with
estrogen (E2), n = 3 per group. (B) 5 day melanin assay of B16F10, WM46 (BRAFV600E),
WM51 (BRAFV600E), and WM3702 (NRASQ61L) cells treated with E2, n = 3 per group. (C)
5 day proliferation assay of B16F10, WM46 (BRAFV600E), WM51 (BRAFV600E), and
WM3702 (NRASQ61L) cells treated with GPER agonist (G-1), n = 3 per group. (D) 5 day
melanin assay of B16F10, WM46 (BRAFV600E), WM51 (BRAFV600E), and WM3702
(NRASQ61L) cells treated with G-1, n = 3 per group. (E) 3 day proliferation assay of
B16F10 cells treated with a dose response of G-1, * denotes significance One-way
ANOVA with Tukey’s multiple comparison test, n = 5 per group. (F) Western blot of
B16F10 cells treated for 16 hours with a saturating dose response of G-1. (G) Western
blot of melanoma cell lines for ERα with MCF7 breast cancer cells as a positive control.
(H) Western blot of YUMM1.7 cells transduced with shRNA’s targeting GPER. (I)
Western blot of YUMM1.7 cells transduced with shRNA’s targeting GPER treated with
500nM G-1. (J) 5 day proliferation assay of YUMM1.7 cells transduced with shRNA’s
targeting GPER treated with 500nM G-1, n = 3 per group. All error bars equal the
standard deviation of the samples.
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Figure 3.3. GPER signaling results in loss of c-Myc in melanoma. (A-C) Western blots of
heMel (A), WM46 (B), and B16F10 (C) melanoma transiently treated with 25nM E2 for 3
days, followed by 4 day withdraw. (D) Western blot of WM46 cells treated with 500nM G1 for 16 hours. (E) Western blot of luciferase- or c-Myc-transduced WM46 cells treated
with 500nM G-1 for 16 hours. (F) Western blot of WM46 cells treated with 500nM G-1,
1μM G-36 (GPER antagonist), or a combination for 16 hours. (G) Western blot of WM46
cells treated with G-1 across a time course. (H) Western blot of WM46 cells treated with
G-1, 100μM PKA inhibitor Rp-8-Br-cAMPS (PKAi), or both for 1 hour. (I) Western blot of
WM46 cells treated with 500nM G-1, 2.5μM proteasome inhibitor (MG132), or both for 1
hour. (J) Western blot of WM46 cells treated with 10μg/ml cyclohexamide (CHX) with
and without 500nM G-1.
82

Figure 3.3-figure supplement 1. Markers of GPER activation in vivo. (A) Western blot
of WM46 cells treated for 16 hours with increasing concentrations of G-1. (B)
Experimental timeline of WM46-bearing mice treated with vehicle or G-1, n = 5 per
group. (C) Immunohistochemistry staining of WM46 tumors treated with either vehicle or
G-1 with quantification of staining on right, * denotes significance by the Mann-Whitney
test. Scale bars = 100μM.
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Figure 3.4. Transient GPER activation inhibits proliferation and augments response to
immunotherapy. (A-C) Western blots of B16F10 (A), WM46 (B), and YUMM 1.7 (C)
melanoma cells after transient treatment with a pregnancy-associated concentration of
E2 (25 nM) or an optimized concentration of G-1 (500 nM). (D) Experimental timeline of
vehicle or 500nM G-1 pre-treatment of B16F10 cells followed by treatment with either
αPD-1 antibody or isotype antibody control (2A3), n=5 per group. (E) Tumor volumes of
treatment groups at Day 14, * denotes significance One-way ANOVA with Tukey’s
multiple comparison test. (F) Survival curve of mice with tumors pre-treated with vehicle
or G-1, followed by isotype antibody control (2A3) or αPD-1 antibody. Significance
between groups by the Log-Rank (Mantel-Cox) test is listed in the table below.
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Figure 3.4. GPER activation inhibits YUMM1.7 melanoma in SCID mice. (A)
Experimental outline of YUMM1.7-bearing SCID mice treated with vehicle or G-1, n = 5.
(B) Tumor volumes over time in two treatment groups, * denotes significance by the
Mann-Whitney test. (C) Survival curve of YUMM1.7-bearing mice treated with vehicle or
G-1, significance by the Log-Rank (Mantel-Cox) test.
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Figure 3.5. Treatment of melanoma-bearing mice with G-1 and αPD-1 immunotherapy
dramatically extends survival. (A) Experimental timeline of B16F10-bearing mice treated
with vehicle or G-1, as well as αPD-1 antibody or isotype antibody control (2A3), n = 10
per group. (B) Tumor volumes of treatment groups at Day 14, * denotes significance
One-way ANOVA with Tukey’s multiple comparison test. (C) Survival curve of mice
treated with vehicle or G-1, as well as isotype antibody control (2A3) or αPD-1 antibody.
Significance between groups by the Log-Rank (Mantel-Cox) test is listed in the table
below. (D) Experimental outline of YUMM1.7-bearing mice treated with vehicle or G-1,
as well as isotype antibody control (2A3) or αPD-1 antibody. Treatment was started at
day 14 after tumors reached 4-5 mm in diameter. n = 5 per group. (E) Tumor volumes
over time of treatment groups. (F) Survival curve of mice treated with vehicle or G-1, as
well as αPD-1 antibody or isotype antibody control (2A3). Significance between groups
by the Log-Rank (Mantel-Cox) test is listed in the table below.
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Figure 3.5-figure supplement 1. G-1 treatment in vivo alters tumor infiltrating immune
cells. (A) Experimental timeline for vehicle or G-1 treatment of YUMM 1.7 melanomabearing mice. (B) Heatmap summarizing immune profiling across biological replicates, n
= 5 per group, * denotes significance by two-way ANOVA assuming each immune
population is an independent measurement of immune activation. (C) Quantification of
individual immune populations from (B), n = 5 per group. (D) Immunohistochemistry
highlighting CD8+ T cells in central or peripheral edge regions of YUMM 1.7 tumors
treated with vehicle or G-1. Quantification of staining on right, n = 3 per group, scale bars
= 50μM.
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Figure 3.6. Tumor clearance with G-1 and αPD-1 combination treatment is associated
with immune memory. (A) Experimental outline of YUMM1.7-bearing mice treated with
vehicle or G-1 and αPD-1 antibody, treatment was started at day 3, n = 10. (B) Survival
curve of mice treated G-1 and αPD-1 antibody compared to historical controls, 5 mice
had no evidence of disease at day 100 and were considered “cleared”. (C) Control and
Cleared mice were challenged with YUMM 1.7 tumors, tumor volumes were measured
over time, *denotes significance by 2way-ANOVA. (D) Tumor volumes of Control and
Cleared mice on day 25, * denotes significance by the Mann-Whitney test. (E)
Representative images of Control and Cleared mice on day 25. (F) Survival curve of
Control and Cleared mice challenged with YUMM1.7 tumors, significance by the LogRank (Mantel-Cox) test.
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Figure 3.6-figure supplement 1. YUMM1.7 tumor clearance is associated with B16F10
immunity. (A) Control and Cleared mice were challenged with B16F10 tumors, tumor
volumes were measured over time, *denotes significance by 2way-ANOVA. (B) Survival
curve of Control and Cleared mice challenged with B16F10 tumors, significance by the
Log-Rank (Mantel-Cox) test.
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Figure 3.7. Model depicting mechanisms through which GPER signaling may
antagonize melanoma.
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DISCUSSION
Although five decades of clinical experience strongly suggest that female sex
hormones protect against melanoma, the mechanisms through which pregnancy, or
estrogen, influence melanoma have gone relatively unexplored. A pharmacologic
approach that recapitulates the female/pregnancy protective effects in men, and women
who have not been pregnant, might significantly diminish the overall melanoma burden.
Progress in this area has likely been limited by the fact that estrogen effects in
melanocytes are not mediated by the well-known nuclear estrogen receptors, but rather
through the nonclassical G protein coupled receptor GPER, which was only recently
demonstrated to be expressed in melanocytes (Natale et al., 2016). Here we
demonstrate that this nonclassical estrogen signaling promotes differentiation in
melanoma, inhibits tumor cell proliferation, and critically, promotes a phenotype that
renders tumors more susceptible to immune-mediated elimination (Figure 3.7).
Consistent with this, recent independent work from others has demonstrated that GPER
protein levels are higher in human pregnancy-associated melanoma compared to
melanoma from non-pregnant females or men, and that high GPER expression is
associated with favorable prognostic indicators including decreased Breslow depth,
decreased mitotic rate, and increased lymphocyte infiltration into tumor (Fabian et al.,
2017). Conclusions from our current study are consistent with those clinical
observations. While this manuscript was under review, independent groups also reported
that G-1 inhibits melanoma cell proliferation in culture (Ribeiro et al., 2017). A second
group demonstrated that GPCR signaling through the endothelin receptor influences
response to targeted therapies (Smith et al., 2017).
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We determined that one of the major mechanisms through which GPER signaling
antagonizes melanoma is thorough depletion of c-Myc protein. c-Myc drives many
cancers including melanoma, and despite intensive effort since its discovery nearly 40
years ago, efforts to inhibit c-Myc with systemically-tolerated agents have generally been
unsuccessful, and there are still no FDA approved c-Myc inhibitors. High c-Myc protein in
tumor cells inhibits expression of antigen presenting HLA/MHC (Schlagbauer-Wadl et al.,
1999) and activates expression of PD-L1 (Casey et al., 2016; Kim et al., 2017). The
combined effects of c-Myc activation render tumors less visible to immune cells.
Consistent with this, GPER-induced c-Myc depletion in our study was accompanied by a
reciprocal increase in HLA/MHC protein, a decrease in PD-L1 (Figure 3.3D), and an
increased susceptibility to immune checkpoint inhibitor therapy.
Several lines of evidence in this work all indicate that the GPER agonist G-1 has
significant tumor-cell intrinsic anti-melanoma activity. First, we show in Figure 3.2 that
pretreatment of mouse melanoma cells with GPER agonist in vitro drives durable cellular
differentiation that inhibits subsequent tumor growth in mice. Consistent with this, G-1
pretreatment of human melanoma cells also inhibited subsequent tumor growth in SCID
mice, indicating that G-1 has anti-tumor activity that is independent of CD4+ or CD8+ T
cells. Further indicative of a tumor cell intrinsic effect of GPER agonist, we demonstrated
that pretreatment of murine melanoma in vitro with GPER agonist still potentiates the in
vivo anti-tumor activity of αPD-1 immune checkpoint blockade (Figure 3.4D-F). Finally,
murine YUMM melanoma tumors established in SCID mice (lacking CD4+ and CD8+ T
cells) are also inhibited by systemically delivered G-1 (Figure 3.4-figure supplement 1).
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Together, these data strongly support the model in which GPER agonists promote
immune clearance of tumor by acting on the tumor cells themselves.
To our knowledge, this is the first work to demonstrate the potential therapeutic
utility of combining GPER agonists or other differentiation-based therapy with cancer
immunotherapy for any cancer type — an approach that may also prove useful for other
cancers. Differentiation drivers likely have very large “therapeutic windows” as anticancer agents. Melanocytes (and other GPER expressing cells) normally respond to
physiologic GPER activation through endogenous estrogen exposure, and the synthetic
specific GPER agonist G-1 is well tolerated in mice. Although no approved drugs target
GPER, GPCRs are biologically important and are generally highly “drugable”, as up to
40% of all FDA approved medications act through these receptors. To our knowledge,
this work is the first to discover the potential therapeutic utility of combining a GPCR
agonist with immunotherapy. As many tumor types express GPER, the selective agonist
G-1 may ultimately prove useful in combination therapy for many human cancers.
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METHODS
Cell culture and cell lines
Primary human melanocytes were extracted from fresh discarded human foreskin and
surgical specimens as previously described (McNeal et al., 2015) with some
modifications detailed as follows. After overnight incubation in Dispase, the epidermis
was separated from the dermis and treated with trypsin for 10 min. Cells were pelleted
and plated in selective melanocyte Medium 254 (Invitrogen, Carlsbad, CA, USA) with
Human Melanocyte Growth Supplement, and 1% penicillin and streptomycin (Invitrogen).
B16F10 melanoma cells were a gift from Andy Minn (University of Pennsylvania
Institute, Philadelphia, PA, USA). WM46 melanoma cells were a gift from Meenhard
Herlyn (Wistar Institute, Philadelphia, PA, USA). YUMM1.7 melanoma cells were a gift
from Ashani Weeraratna (Wistar Institute, Philadelphia, PA, USA) and Marcus
Bosenberg (Yale University, New Haven, CT, USA). These cell lines were verified to be
of melanocyte origin by response to alpha melanocyte stimulating hormone and melanin
production. Human-engineered melanoma cells (heMel) were cultured in Medium 254,
WM46 cells were cultured in TU2% media, B16F10 and YUMM1.7 cells were cultured in
DMEM (Mediatech, Manassas, VA, USA) with 5% FBS (Invitrogen) and 1% antibioticantimycotic (Invitrogen). Cells were transduced with lentiviruses as described previously
(McNeal et al., 2015). The following shRNAs were expressed from the pLKO vector and
are

available

from

The

RNAi

GAGCATCAGCAGTACGTGATT)

Consortium:
and

shGPER.1

shGPER.2

(TRCN0000026391,
(TRCN0000026405,

GCCACGCTCAAGGCCGTCATT). Progesterone (P8783) and 17β-Estradiol (E8875)
were purchased from Sigma-Aldrich (St. Louis, MO, USA). G-1 (10008933) and G-36
94

(14397) were purchased from Cayman Chemical (Ann Arbor, MI, USA). Rp-8-Br-cAMPS
was purchased from Santa Cruz Technologies (Dallas, Texas, USA). These compounds
were diluted to working stock solutions in Medium 254.
Mice
All mice were purchased from Taconic (Hudson, NY, USA). Five to seven week old
female immune deficient (ICR SCID) and syngeneic (C57BL/6NTac) mice were allowed
to acclimatize for one week prior to being used for experiments. These studies were
preformed without inclusion/exclusion criteria or blinding, but included randomization.
Based on a twofold-anticipated effect, we performed experiments with at least 5
biological replicates. All procedures were performed in accordance with International
Animal Care and Use Committee (IACUC)-approved protocols at the University of
Pennsylvania.
Human-engineered melanoma xenografts
Organotypic skin grafts were established using modifications to previously detailed
methods (McNeal et al., 2015). The Keratinocyte Growth Media (KGM) used for
keratinocyte-only skin grafts was replaced with modified Melanocyte Xenograft Seeding
Media (MXSM). MXSM is a 1:1 mixture of KGM, lacking cholera toxin, and Keratinocyte
Media 50/50 (Gibco) containing 2% FBS, 1.2 mM calcium chloride, 100 nM Et-3
(endothelin 3), 10 ng/mL rhSCF (recombinant human stem cell factor), and 4.5 ng/mL rbasic FGF (recombinant basic fibroblast growth factor). Briefly, primary human
melanocytes

were

transduced

with

lentivirus

carrying

doxycycline-inducible

BRAF(V600E), dominant-negative p53(R248W), active CDK4(R24C) and hTERT.
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Transduced melanocytes (1.5 x 105 cells) and keratinocytes (5.0 x 105 cells) were
suspended in 80 μL MXSM, seeded onto the dermis, and incubated at 37˚C for 4 days at
the air-liquid interface to establish organotypic skin. Organotypic skin tisssues were
grafted onto 5-7 week-old female ICR SCID mice (Taconic) according to an IACUC–
approved protocol at the University of Pennsylvania. Mice were anesthetized in an
isoflurane chamber and murine skin was removed from the upper dorsal region of the
mouse. Organotypic human skin was reduced to a uniform 11 mm × 11 mm square and
grafted onto the back of the mouse with individual interrupted 6-0 nylon sutures. Mice
were dressed with Bactroban ointment, Adaptic, Telfa pad, and Coban wrap. Dressings
were removed 2 weeks after grafting and the tissue was allowed to stabilize for an
additional week before mice were switched over to doxycycline chow (6g/kg, Bio-Serv,
Flemington, NJ) for 15 weeks.
Subcutaneous tumors and treatments
Subcutaneous tumors were initiated by injecting tumor cells in 50% Matrigel (Corning,
Bedford, MA, USA) into the subcutaneous space on the left and right flanks of mice. For
each type of tumor injection, 4 x 104 B16F10 cells were used, 1 x 106 WM46 cells were
used, and 1 x 105 YUMM1.7 cells were used. In vivo G-1 treatments were performed by
first dissolving G-1, synthesized as described previously (Natale et al., 2016), in 100%
ethanol at a concentration of 1mg/ml. The desired amount of G-1 was then mixed with
an appropriate volume of sesame oil, and the ethanol was evaporated off using a Savant
Speed Vac (Thermo Fisher Scientific, Waltham, MA, USA), leaving the desired amount
of G-1 dissolved in 50μL of sesame oil per injection at a 0.4mg/kg dose for B16F10
experiments, and 10mg/kg dose for YUMM1.7 experiments. Vehicle injections were
96

prepared in an identical manner using 100% ethanol. Vehicle and G-1 injections were
delivered through subcutaneous injection as indicated in each experimental timeline.
Isotype control antibody (Clone: 2A3, BioXcell, West Lebanon, NH, USA) and αPD-1
antibody (Clone: RMP1-14, BioXcell) were diluted in sterile PBS and delivered through
intraperitoneal injections at a dose of 10mg/kg.
Survival Analysis
As subcutaneous tumors grew in mice, perpendicular tumor diameters were measured
using calipers. Volume was calculated using the formula L × W^2 × 0.52, where L is the
longest dimension and W is the perpendicular dimension. Animals were euthanized
when tumors exceeded a protocol-specified size of 15 mm in the longest dimension.
Secondary endpoints include severe ulceration, death, and any other condition that falls
within the IACUC guidelines for Rodent Tumor and Cancer Models at the University of
Pennsylvania.
Western Blot Analysis
Adherent cells were washed once with DPBS, and lysed with 8M urea containing 50mM
NaCl and 50mM Tris-HCl, pH 8.3, 10mM dithiothreitol, 50mM iodoacetamide. Lysates
were quantified (Bradford assay), normalized, reduced, and resolved by SDS gel
electrophoresis on 4–15% Tris/Glycine gels (Bio-Rad, Hercules, CA, USA). Resolved
protein was transferred to PVDF membranes (Millipore, Billerica, MA, USA) using a
Semi-Dry Transfer Cell (Bio-Rad), blocked in 5% BSA in TBS-T and probed with primary
antibodies recognizing β-Actin (Cell Signaling Technology, #3700, 1:4000, Danvers, MA,
USA), BRAF V600E (Spring Bioscience, VE1, 1:500, Pleasanton, CA, USA) c-Myc (Cell
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Signaling Technology, #5605, 1:1000), CDK4 (Cell Signaling Technology, #12790,
1:1000), p-CREB (Cell Signaling Technology, #9198, 1:1000), CREB (Cell Signaling
Technology, #9104, 1:1000), ERα (Cell Signaling Technology, #8644, 1:1000), GPER
(Sigma, HPA027052, 1:500), HLA-ABC (Biolegend, w6/32,1:500, San Diego, CA, USA),
MC1R (Abcam, EPR6530, 1:1000 Cambridge, MA, USA), p53 (Cell Signaling
Technology, #2527, 1:1000), human PD-L1 (Cell Signaling Technology, #13684,
1:1000), mouse PD-L1 (R&D systems, AF1019, 1:500, Minneapolis, MN, USA), p-RB
(Cell Signaling Technology, #8516, 1:1000), RB (Cell Signaling Technology, #9313,
1:1000), and tyrosinase (Abcam, T311, 1:1000). After incubation with the appropriate
secondary antibody, proteins were detected using either Luminata Crescendo Western
HRP Substrate (Millipore) or ECL Western Blotting Analysis System (GE Healthcare,
Bensalem, PA). All western blots were repeated at least 3 times.
Melanin Assay
Cells (1 x 105) cells were seeded uniformly on 6-well tissue culture plates. Cells were
treated with vehicle controls, estrogen, or G-1 for 4 days. Cells were then trypsinized,
counted, and spun at 300 g for 5 minutes. The resulting cell pellet was solubilized in 120
μL of 1M NaOH, and boiled for 5 min. The optical density of the resulting solution was
read at 450 nm using an EMax microplate reader (Molecular Devices, Sunnyvale, CA,
USA). The absorbance was normalized to the number of cells in each sample, and
relative amounts of melanin were set based on vehicle treated controls. All melanin
assays were repeated at least 3 times
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Immunohistochemistry and Quantification
Formalin fixed paraffin embedded (FFPE) human skin tissue sections from organotypic
tissue was stained for MITF (NCL-L-MITF, Leica Biosystems, Nussloch, Germany),
MelanA

(NCL-L-MITF,

Leica

Biosystems),

and

Ki67

(NCL-L-Ki67-MM1,

Leica

Biosystems). Staining was performed following the manufacturer protocol for high
temperature antigen unmasking technique for paraffin sections. For melanin staining
FFPE embedded tissue was subjected to Fontana-Masson histochemical stain as
previously described (Natale et al., 2016).
FFPE subcutaneous tumor tissue sections were stained for CD8 (Cell Signaling
Technology, #98941, 1:400), p-CREB (Cell Signaling Technology, #9198, 1:800), c-Myc
(Abcam, ab32072, 1:100), GPER (Novus Biologics, NLS1183, 1:50, Littleton, CO, USA).
Briefly, tissue sections were de-paraffinized, rehydrated, and subjected to heat induced
antigen retrieval. Antigen retrieval was performed in 10mM citrate buffer, pH 6.0 for CD8,
p-CREB, and c-Myc; Tris-EDTA, pH 8.0 (Thermo Fisher Scientific, BP2473-1) was used
for GPER. Subsequent staining procedures were performed following the manufacturer
protocol from the HRP/DAB detection kit (Abcam, ab80436). Sections were counter
stained with hematoxylin, dehydrated, and cover slipped with Permount Mounting Media
(Thermo Fisher Scientific).
Tissue section quantification was performed according to Billings et al. 2015. Briefly, 20X
photomicrograph images of representative tissue sections were taken using the Zeiss
Axiophot microscope and Keyence BZ-X710 (Itasca, IL, USA). Tiff files of the images
were saved and transferred to Adobe Photoshop where pixels corresponding to staining
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were selected using the color selection and lasso selection tools. Images corresponding
to the single specific color were then analyzed using FIJI (Image J) to determine the
number of pixels in each sample and normalized to epidermal area. The numbers of
pixels representing Fontana-Masson staining were normalized to the total amount of
epidermal area. Ki67 proliferation index was calculated by dividing the number Ki67
positive cells by the total number of MelanA positive cells in the samples.
Flow Cytometry
Cell surface markers were assessed by incubating single cell suspensions of tissues
with primary fluorochrome-labeled antibodies at 4°C for 60 min in PBS with 5% FBS;
FITC-anti-mouse-Nkp46 (29A1.4, Biolegend, #137606, 1:50), PE-CF594-anti-mouseCD8a (53-6.7, BD Pharmingen, #562283, 1:100), PE-Cy5-anti-mouse-CD3ε (145-2C11,
Biolegend, #100310, 1:100, PE-Cy7-anti-mouse-I-A/I-E (M5/114.15.2, Biolegend,
#107630, 1:600), V450-anti-mouse-CD44 (IM7, Biolegend, #560451, 1:100), AF700-antimouse-CD45 (30-F11, Biolegend, #103128, 1:400), APC-Cy7-anti-mouse-F4/80 (BM8,
Biolegend, #123118, 1:100), PerCP-Cy5.5-anti-mouse-CD11b (M1/70, BD Pharmingen,
#550993, 1:200), BV570-anti-mouse-CD62L (MEL-14, Biolegend, #104433, 1:50),
Live/Dead Fixable Aqua Dead Cell Stain Kit, for 405nm excitation (Thermo Fisher
Scientific,

L-34966,

1:600).

Intracellular

staining

was

done

using

the

Fixation/Permeabilization Kit from eBiosciences. Flow cytometric analysis was
performed on LSR II Flow Cytometer (BD Biosciences). Collected data were then
analyzed using the FlowJo software (Treestar, Ashland, Oregon, USA).
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Statistical Analysis
All statistical analysis was performed using Graphpad Prism 8 (Graphpad Software, La
Jolla, CA, USA). No statistical methods were used to predetermine sample size. Details
of each statistical test used are included in the figure legends.
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CHAPTER 4: FUTURE DIRECTIONS

OVERVIEW
The data presented thus far may represent a foundation for several avenues of
future research. In Chapter 2, we identified two nonclassical sex hormone receptors,
GPER and PAQR7, which upregulate and downregulate melanocyte differentiation,
respectively. In Chapter 3, we built upon this discovery and utilized GPER agonists to
drive differentiation in melanoma cells, which inhibited tumor progression and had
remarkable therapeutic effects when combined with immune checkpoint inhibitors. While
we have firmly established the importance of these nonclassical sex hormone signaling
biology underlying these effects, as well as the application of these findings to other
biological contexts. For example, we have established that the pro-differentiation effects
of GPER signaling are durable, but the lasting epigenetic changes responsible for
maintaining these effects are unknown. After GPER activation and rapid c-Myc
depletion, what are the durable transcriptional changes that reinforce the growthinhibited phenotype? What is the role of constitutive pigmentation/differentiation in the
oncogenic potential of melanocytes? Might the inhibition of differentiation through
progesterone and PAQR7 signaling promote tumorigenesis? Do these signaling
pathways apply to other tumor types beyond melanoma? While it may be considered a
cliché in research, there are certainly more questions to ask now that our initial
hypothesis has been tested. In this chapter, I discuss the primary literature and our
unpublished preliminary data relating to these open questions.
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UNDERSTANDING THE EPIGENETIC AND TRANSCRIPTIONAL CHANGES AFTER
GPER ACTIVATION
In Chapter 2, we showed that GPER signaling through cAMP, PKA, and p-CREB
ultimately results in heightened melanocyte differentiation. We went on to demonstrate
that the differentiation was durable; when a GPER agonist was removed, melanocytes
and melanoma cells stably produced more pigment, expressed higher levels of
melanocyte differentiation proteins, and expressed lower levels of proliferation markers.
This rapid downstream signaling from GPER translated into a long-lasting effect,
suggesting that GPER activation and downstream p-CREB signaling may induce longlasting epigenetic changes. Although epigenetic transcriptional memory has not yet been
described as a feature of GPCR or CREB signaling, CREB target genes have been
implicated in addiction to drugs, including cocaine and amphetamines (McClung and
Nestler, 2003), and addiction is thought to partly result from epigenetic changes in the
brain (Heller et al., 2016).
To begin to identify the epigenetic changes likely responsible for the memory,
we used mass spectrometry in collaboration with Dr. Benjamin Garcia (University of
Pennsylvania) to obtain a global analysis of histone post-translational modifications in
melanocytes transiently treated with estrogen. Consistent with a mechanism involving
CREB activity, we observed significant increases (in three independent biologic
replicates) in many histone acetylation marks including H3K122ac, H3K56ac, H3K23ac,
and H3K18ac that are written by the CREB-binding histone acetylransferases CBP/P300
(Figure 4.1A). In contrast, the H3K9ac mark, which is not written by CBP/P300, was
decreased following estrogen treatment. As histone post-translational modifications,
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including acetylation, mediate heritable transcriptional memory in other contexts (Adenot
et al., 1997; Jeppesen, 1997), this suggests that CBP/P300-regulated histone
modifications may maintain underlie the increased melanocyte differentiation across cell
divisions. Consistent with the idea that histone acetylations support melanocyte
differentiation in human tissue, higher levels of CBP-written histone acetyl marks are
observed in benign human nevi, and non-tumorigenic melanoma cells, compared to
melanoma tissues and tumorigenic melanoma cell lines (Fiziev et al., 2017). Next, we
tested whether pharmacologic inhibition of CBP/p300 acetyltransferases can inhibit the
GPER-mediated increase in melanin production (Figure 4.1B). We treated normal human
melanocytes with estrogen and observed a relative increase in melanin production;
however, this increase was attenuated when the cells were also treated with the
CBP/P300 inhibitor C646. Not only was the initial induction blunted with the CBP/P300
inhibitor, there also was no maintenance of the modest induction of melanin production.
We also validated this effect through western blotting the CBP/P300-regulated histone
acetylation H3K56ac (Figure 4.1C). When melanocytes were treated with estrogen we
observed an increase in this histone acetylation, which was blocked with C646.
Together, these data suggest that GPER signaling through CREB activates the
CBP/P300 histone acetylation machinery, which may underlie features of the durable
response after GPER activation. Future work to identify the specific loci where
CBP/P3000 regulated histone acetylations change may provide deeper insight into the
transcriptional programs responsible for establishing and maintaining the melanocyte
differentiation program.
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Histone acetyl marks are removed by several histone deacetylases (HDACs),
which are aberrantly regulated in many cancers. Although HDAC inhibitors are approved
as anticancer agents for cutaneous lymphoma, myeloma and pancreatic cancer, their
utility in melanoma is unclear. In human trials, HDAC inhibitors generally displayed only
modest anti-melanoma activity as monotherapy agents, although some patients did have
significant responses (Hornig et al., 2016). The efficacy of HDAC inhibitors may have
been limited by the relative lack of histone acetylations that promote differentiation;
HDAC inhibitors cannot stabilize histone acetylations if these modifications are not
present. This suggests that the efficacy of HDAC inhibitors may be increased if they are
combined with agents that promote histone acetylation, like GPER agonists. To test this,
we treated B16F10 mouse melanoma cells with vehicle, G-1, pracinostat (HDAC
inhibitor), or a combination of both agents. Treatment with a combination of G-1 and
pracinostat resulted in a marked decrease in the proliferation marker p-RB as well as a
marked increase in H3K56ac; these effects were larger than observed with either agent
alone (Figure 4.1D). Next, we performed a proliferation assay to directly test the effects
of these agents on proliferation. While treatment with either G-1 or pracinostat slowed
B16F10 proliferation, the combination of both agents induced a relative growth arrest,
which is remarkable given the aggressive nature of this tumor line (Figure 4.1E). Future
studies examining the combinatorial effects of HDAC inhibitors and GPER agonists in
vivo may further elucidate the therapeutic potential of these two classes of agents,
especially if immune checkpoint inhibitors are included as part of a trimodal therapy.
Recent investigations with HDAC inhibitors and immunotherapies are promising,
suggesting that adding GPER agonists to this regimen may have significant therapeutic
potential (Hornig et al., 2016).
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Next, we aimed to understand global changes in transcription after GPER
activation in collaboration with Dr. Brian Capell (University of Pennsylvania). We isolated
three biological replicates of normal human melanocytes, and treated them for seven
days with the GPER agonist G-1. RNA-seq was performed and data was processed
using DEseq2 analysis, a bioinformatic tool to analyze differences in gene expression,
resulting in 275 statistically significant upregulated transcripts, as well as 499 statistically
significant downregulated transcripts (Figure 4.2A). Gene ontology analysis of the G-1
induced changes show that there is a strong upregulation of transcripts involved in
interferon signaling, which are necessary for immunotherapy response (Minn and
Wherry, 2016), as well as tumor suppressors genes (Figure 4.2B). Gene ontology
analysis of negatively regulated genes shows enrichment for cell cycle and mitotic
regulators, consistent with the tumor growth phenotypes (Figure 4.2B). The top induced
and reduced genes can be used to identify correlations in the melanoma TCGA RNA-seq
datasets. The top 10 induced genes are elevated to varying degrees in the TCGA
dataset, and the elevation of these transcripts is associated with a statistically significant
increase in patient survival (Figure 4.2C). This suggests that the G-1 induced transcripts
represent genes that are associated with better patient outcomes. The top 10 reduced
genes are elevated to varying degrees in this data set, and the elevation of these
transcripts is associated with a statistically significant decrease in patient survival (Figure
4.2D. This suggests that the G-1 reduced transcripts represent genes that are
associated with worse patient outcomes. While these data merely represent correlations,
it certainly suggests that GPER signaling induces large-scale transcriptional changes
that are generally tumor suppressive.
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One of the top G-1 induced genes is B-cell translocation gene 2 (BTG2), which is
a known tumor suppressor in several other cancer types. BTG2 is regulated by CREB
(Tan et al., 2012), consistent with our finding that GPER signals through the
cAMP/PKA/CREB axis in melanocytes and melanoma. BTG2 is expressed in many
tissues, including lung, pancreas, prostate, thymus, spleen, stomach, and intestine
(Melamed et al., 2002). A wide range of tumor suppressive functions has been attributed
to BTG2. BTG2 induction can drive cellular differentiation in both nerve and
hematopoietic cells (Cho et al., 2008). In gastric and lung cancer cells, BTG2 inhibits
cell cycle, suggesting an anti-proliferative role (Wei et al., 2012; Zhang et al., 2010). In
response to a p53 DNA damage response, BTG2 expression is upregulated, suggesting
a potential role in DNA repair (Zhang et al., 2011). Together, these previous reports
suggest that BTG2 plays a multitude of roles in tumor suppression, and may be a critical
downstream component of the GPER signaling response we observe in melanoma. To
validate our RNA-seq studies in primary human melanocytes, we have validated that
BTG2 is induced in human melanoma cells when treated with G-1 (Figure 4.2E). Future
studies demonstrating the necessity and sufficiency of BTG2 as a tumor suppressor in
melanoma may validate this gene as an important factor.
THE ROLE OF CONSTITUTIVE PIGMENTATION IN MELANOMAGENESIS
The majority of the work presented thus far revolves around the modulation of
facultative pigmentation and differentiation, which alters the ability of melanoma to grow
and proliferate. The lessons learned from this work may also be applied further to
understand how constitutive pigmentation, or baseline pigmentation, contributes to
melanomagenesis. It is clear that melanocytes play a vital role in producing pigment that
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protects the epidermis from UVR-induced damage, ultimately conferring a resistance to
formation of skin cancers. This is supported by epidemiological data that shows that skin
cancer represents ~35–45% of all neoplasms in Caucasians, 4–5% in Hispanics, 2–4%
in Asians, and 1–2% in those with African ancestry (Gloster and Neal, 2006; Ridky,
2007). It is clear that the photoprotective properties influence the formation of squamous
cell carcinoma and basal cell carcinoma within the epidermis, but whether this extends to
melanocytes is unclear.
The UVR-shielding effect of melanin is thought to underlie the 70-fold difference
in skin cancer rates between white and black skin (Halder and Bang, 1988), yet the
ability of melanin to act as a sunscreen is seemingly limited. Studies aimed to measure
the sun protection factors (SPF) of dark skin have found that melanin only provides and
SPF of 1.5-2, suggesting that black skin can filter only about twice as much UVR than
white skin (Gloster and Neal, 2006). The distribution of melanin plays a large role in its
photoprotective function; in keratinocytes melanin is trafficked to the perinuclear area
forming a suprabasal cap, which is thought to shield and scatter UVR before it reaches
the nucleus of these cells (Kobayashi et al., 1998). This is thought to be critical for
melanin to serve as a UVR filter, as melanin in white skin fails to produce stable caps on
keratinocytes. To the best of our knowledge, there have been no studies documenting
the presence of suprabasal melanin caps in melanocytes, suggesting that while
melanocytes produce melanin to protect keratinocytes from UVR, they may not be
protected in a similar way. In addition to the potential lack of UVR protection provided by
melanin in melanocytes, other data suggests that there may be more to the racial bias in
melanoma than melanin itself. Anorectal melanoma, which is classified as mucosal
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melanoma, has similar oncogenic mutations as cutaneous melanoma (Yang et al.,
2017). Even though this type of lesion develops on a sun-protected area, there is still a
racial bias in this disease. In epidemiological studies from the United States, it was found
that there was a 13-fold higher rate of anorectal melanoma in those with white skin
compared to those with black skin (Callahan et al., 2016). Perhaps the most intriguing
data suggesting that pigment within the skin may not be the root of the racial bias in
melanoma comes from epidemiological studies on albino individuals in Africa
(Fitzpatrick, 1989). Studies on skin cancer rates of individuals with oculocutaneous
albinism (who still have melanocytes) in Africa have shown that these individuals have
an extremely high rate of invasive squamous and basal cell carcinoma. Curiously, the
rates of melanoma in these individuals remained extraordinarily low (Kiprono et al.,
2014), suggesting that while their skin is phenotypically white, their incidence of
melanoma parallels those with black skin. Together, the lack of substantial UVR
protection from melanin, the racial bias in sun-protected melanoma, and the low
incidence of melanoma in African albinos suggests that there is more to the racial bias in
melanoma than simply the color of an individual’s skin. A running hypothesis is that the
level of constitutive pigmentation in a person’s skin is indicative of the state of
differentiation of their melanocytes; those with dark skin have more differentiated
melanocytes that are resistant to oncogenic transformation, while those with light skin
have more undifferentiated melanocytes that are more likely to form melanoma.
To test whether constitutive pigmentation influences aspects of tumorigenesis,
we utilized the Penn Dermatology Disease Research Core to obtain 13 biological
replicates of primary human melanocytes, which displayed a wide range of baseline
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pigment levels (Figure 4.3A). To begin, we performed a concurrent melanin and
proliferation assay on these 13 batches of melanocytes, which resulted in a strong
inverse correlation; melanocytes that produced the most pigment were the least
proliferative, and melanocytes that produced the least pigment were the most
proliferative (Figure 4.3B). Bright-field microscopy images of the lightest (LMC) and
darkest (DMC) set of melanocytes highlight the marked differences in pigment
production (Figure 4.3C). To examine these cells further, we took the three darkest and
three lightest melanocytes and performed a western blot for p-RB and c-Myc. We
observed an increase in both p-RB and c-Myc in light melanocytes relative to the dark
melanocytes (Figure 4.3D), consistent with the less differentiated melanocytes being
more proliferative and may be more easily transformed. Next, we were interested in
knowing whether these changes in proliferation, p-RB, and c-Myc were maintained when
these cells harbored oncogenic mutations. As we have done previously, we transduced
LMC and DMC isolates with BRAFV600E (doxycycline-inducible), dominant-negative
p53R248W, active CDK4R24C, and hTERT to generate human-engineered melanoma cells.
When assaying the LMC and DMC for proliferation, LMC heMel proliferated faster than
DMC heMel independent of oncogene transduction (Figure 4.3E). We also performed a
western blot on LMC and DMC heMel cells for markers of proliferation and melanocyte
differentiation. LMC heMel cells had higher levels of proliferation markers including p-RB
and c-Myc and reduced levels of melanocyte differentiation markers like p-CREB and
TYR, relative to the DMC heMel cells (Figure 4.3F). Together, these data suggest that
lightly pigmented melanocytes are more proliferative, express more c-Myc, and have
lower levels of melanocyte differentiation proteins than dark melanocytes, and that this
difference is not altered by oncogene expression.
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To

directly

test

whether

constitutive

pigmentation

contributes

to

melanomagenesis, we plan to compare the oncogenic potential of light and and dark
heMel cells in vivo. While it would be optimal to show these differences in our orthotopic
xenograft model of melanoma, this would not be economical due to the cost, time, and
labor associated with this model, as we would need to produce upwards of five replicates
of many melanocyte isolations to have enough power to demonstrate reproducible
differences in melanomagenesis. To that end, we are currently establishing and
validating a new subcutaneous tumor model with engineered melanocytes. This
approach will allow us to transduce many melanocyte isolations with oncogenes in
parallel, form tumors in mice, and assay the rate of tumor growth. Assuming there are
still notable differences between lightly and darkly pigmented cells in vivo, next
generation sequencing can be utilized to further understand the genetic and
transcriptional differences that underlie the tumorigenic potential of different melanocyte
isolates. This future work may contribute to the larger understanding of biological
differences between races regarding cancer.
UNDERSTANDING THE EFFECT OF PROGESTINS IN THE DEVELOPMENT OF
MELANOMA DURING PREGNANCY
In Chapter 2, we identified estrogen/GPER signaling as a driver of melanocyte
differentiation, and progesterone/PAQR7 signaling as a repressor of melanocyte
differentiation. While the clinical evidence suggests that pregnancy is overall protective
against future melanoma, the hormonal milieu during pregnancy may promote
melanomagenesis. Pregnancy is associated with morphologic changes in previously
growth-arrested melanocytic nevi, including darkening in color and increases in size,
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resulting from reengagement of the cell cycle with mitotic activity not otherwise seen in
benign adult nevi (Chan et al., 2010; Lee et al., 2000). In the generally cancersuppressive context of pregnancy, melanoma is the most frequently diagnosed
malignancy (Andersson et al., 2015; Bannister-Tyrrell et al., 2014), and is more invasive
at diagnosis than age-matched, non-pregnant controls (Bannister-Tyrrell et al., 2014). A
recent report has shown that melanoma that develops during pregnancy is associated
with 9-fold increase in recurrence, 7-fold increase in metastasis, and a 5-fold increase in
mortality (Tellez et al., 2016). The data involving melanoma during pregnancy can be
interpreted in two ways: either the cancer-suppressive context of pregnancy selects for a
more aggressive tumor, or there are factors present that promote melanoma during
pregnancy. These explanations of the clinical data may not be mutually exclusive, but
they certainly suggest that while melanoma after pregnancy has a better prognosis,
factors during pregnancy may promote melanomagenesis.
The physiologic effects of estrogen are often counter-balanced by simultaneous
exposure to progesterone (Ismail et al., 2015a). Therefore, it is possible that the ratio of
estrogen and progesterone during pregnancy may dictate the balance between the
protective role of estrogen and tumorigenic effect of progesterone. The serum
concentrations of estrogen and progesterone during human pregnancy vary, ranging
from estrogen to progesterone ratio of about 1:15 to 1:100 during the third trimester
(Abbassi-Ghanavati et al., 2009). PAQR7 can bind to progesterone as well as the
pregnancy-associated progestin, allopregnanolone (Thomas and Pang, 2012), which are
35-fold higher in non-pregnant women than in men, and 157-fold higher in the setting of
a full term pregnancy (Genazzani et al., 1998; Luisi et al., 2000).
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Curiously,

allopregnanolone does not bind to the classical progesterone receptor, suggesting that a
different receptor involvement of a nonclassical receptor like PAQR7 (Thomas and Pang,
2012). Together, this suggests that there may be a role of progestins signaling through
PAQR7 to inhibit differentiation that may promote melanomagenesis during pregnancy.
We originally identified allopregnanolone as a hormone that stimulates growth of
melanocytes and melanoma as part of a high-throughput small molecule screen. This
screen was performed using our doxycycline-inducible BRAFV600E construct in primary
human melanocytes (diBRAF). Induction of BRAFV600E with 0.25μg/ml doxycycline
results in a nevus-like growth arrest (McNeal et al., 2015). Bypass of this growth arrest is
necessary for the transition from benign nevi to melanoma, as up to 42% of melanomas
may arise from preexisting benign nevi (Weatherhead et al., 2007). Using the Spectrum
Chemical Library which contains over 2500 distinct compounds with known biologic
activity, we identified 1144 compounds that stimulated proliferation in BRAFV600Eexpressing, growth-arrested melanocytes (Figure 4.4A). Of the compounds that
stimulated proliferation to the largest degree, allopregnanolone has the most effective
naturally occurring compound (Figure 4.4B). Next, we treated primary human
melanocytes with a dose-response of allopregnanolone, which showed that there is a
dose-dependent increase in proliferation (Figure 4.4C). We treated out diBRAF cells with
250nM allopregnanolone, a physiologically-relevant dose during pregnancy, and showed
a significant increase in proliferation both in control and BRAFV600E-expressing cells
(Figure 4.4D). To test whether allopregnanolone had similar effects in melanoma cells,
we treated B16F10 mouse melanoma cells

with estrogen, progesterone, or

allopregnanolone and assayed for proliferation and melanin production. As we observed
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before, estrogen inhibited proliferation and stimulated melanin production, progesterone
modestly increased proliferation and inhibited melanin production, and allopregnanolone
more significantly enhanced proliferation and inhibited melanin production (Figure 4.4EF). As a preliminary in vivo experiment, we injected B16F10 melanoma cells into male,
non-pregnant female, and pregnant female mice and assayed tumor growth. After two
weeks, the tumors in the pregnant mice were twice as large as the male and female
control mice, suggesting that melanoma growth is stimulated during pregnancy (Figure
4.4G).
Future in vivo studies will be required to definitively determine whether progestins
signaling through PAQR7 are responsible for the enhancement of melanomagenesis
during pregnancy. Progesterone, allopregnanolone, and CH2P4 are all known ligands for
PAQR7, although the biological effects of these ligands may not be equal.
Understanding the metabolism of these ligands in melanoma cells, as well as the ligand
signaling bias with PAQR7 may help elucidate the potential differential effects of these
agents. Necessity of PAQR7 to stimulate melanoma growth during pregnancy could be
determined by using shRNA knockdowns or CRISPR-Cas9 disruptions of PAQR7,
followed by assaying tumor growth during pregnancy as previously preformed (Figure
4.4F). Demonstrating that a PAQR7 agonist is sufficient to stimulate melanomagenesis
in vivo would be critical as well. Several agonists of PAQR7 could be used, including
progesterone, allopregnanolone, or the specific PAQR7 agonist CH2P4, though
progesterone administration is the most cost-effective ligand for in vivo studies. We have
made several initial attempts of delivering progesterone to mice in vivo, including 4%
topical application in DMSO as well as silastic implants containing 20mg of
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progesterone. Unfortunately, both of these delivery techniques resulted in a significant
negative impact on the animals body condition, resulting in early termination of these
studies. Of note, we have tested whether progesterone injections could be used to test
these questions; 1mg injections of progesterone administered three times a week were
well tolerated with no obvious toxicity. As the effects of estrogen and progesterone are
normally balanced by each other, it may also be possible that a low dose of estrogen is
required to be co-administered with progesterone to prevent toxicity. Nonetheless,
overcoming these experimental shortcomings may help to elucidate the role of PAQR7 in
progestin signaling and determine the clinical association between aggressive
melanoma and pregnancy.
DETERMINING WHETHER GPER SIGNALING IS TUMOR SUPPRESSIVE IN OTHER
CANCERS
As evidenced by The Surveillance, Epidemiology, and End Results (SEER) Data
Explorer from the National Cancer Institute, it is clear that many malignancies have a
gender bias with the exception of malignancies that typically only affect effect one sex,
such as breast, ovarian, and endometrial cancers. For such malignancies that only affect
females, there are well-documented protective effects after pregnancy (Bernstein, 2002;
Hankinson et al., 1995; Titus-Ernstoff et al., 2001). We have demonstrated that GPER
signaling in melanoma is tumor suppressive, but it is highly likely that GPER signaling
may underlie the gender/pregnancy-related protective effects in other cancers as well.
After GPER was originally identified in breast cancer cells (Filardo et al., 2002), the
activity of GPER was investigated in many classically hormone-responsive tissues.
GPER signaling was thought to be tumor-promoting in breast cancer, although more
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recent reports have suggested that nonclassical estrogen signaling is likely tumor
suppressive (Wei et al., 2014; Weissenborn et al., 2014a; Weissenborn et al., 2014b). In
other classically hormone-responsive cancers like endometrial, ovarian, and prostate
cancer, GPER signaling has also been shown to be tumor suppressive (Ignatov et al.,
2013; Lam et al., 2014; Skrzypczak et al., 2013). Other recent studies that GPER
signaling is tumor suppressive in cancers that are not traditionally hormone-responsive,
like lung and colon (Liu et al., 2017; Zhu et al., 2016). Together, these reports suggest
that many cancers that express GPER could potentially be targeted with G-1 in
combination with immunotherapy, as we have shown in melanoma.
To investigate the therapeutic potential of GPER agonists combined with
immunotherapy, high quality mouse syngeneic models are required. While B16F10 and
YUMM cell lines are sufficient to investigate immunotherapy combinations in melanoma,
there are limited resources available for other cancer types. Recently, the laboratory of
Dr. Ben Z. Stanger (University of Pennsylvania) has generated a series of syngeneic cell
lines from the K-RasLSL.G12D/+; p53R172H/+; Pdx-Cre mouse model of pancreatic ductal
carcinoma (PDAC). PDAC represents an interesting malignancy to investigate the role of
GPER signaling due to several clinical associations. Like melanoma, parity has been
shown to be associated with decrease risk of PDAC (Zhu et al., 2014). Curiously, the
use of estradiol containing oral contraceptives have also been associated with a
decreased risk of PDAC (Lee et al., 2013), and the expression and relative role of
classical estrogen receptors in pancreatic tumors remains unclear (Satake et al., 2006).
Together, this suggests that PDAC tumors may respond to GPER activation and
immunotherapy, similar to melanoma.
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To examine whether the PDAC tumor lines respond similarly to melanoma, we
performed a dose-response with G-1 in the 2838c3 line. As the concentration of G-1
increased, we observed a reduction in p-RB, c-Myc, and PD-L1, consistent with what we
have observed in melanoma cell lines (Figure 4.5A). Transient treatment with G-1
resulted in a stable depletion of p-RB, c-Myc, and PD-L1, also consistent with what we
observed in melanoma (Figure 4.5B). Treatment of several PDAC lines with G-1
dramatically inhibited proliferation (Figure 4.5C) and reduced the levels of p-RB and cMyc (Figure 4.5D-G). To investigate the role of GPER signaling in vivo, we implanted
2838c3 tumors into syngeneic mice and after one week of tumor growth we treated the
mice with G-1, αPD-1 antibody, or both (Figure 4.5H). After the initial G-1 treatment, all
treated mice had significantly smaller tumors (Figure 4.5I), suggesting that this tumor line
is responding to GPER activation in vivo. As tumor volume was monitored over time, we
observed that αPD-1 modestly extended survival, but in contrast to melanoma, G-1
monotherapy had a more pronounced effect in this PDAC line. The combination therapy
of G-1 and αPD-1 resulted in a dramatically extended survival, resulting in 60% of mice
having no evidence of disease 100 days after the initial tumor implantation. Together,
these data suggest that PDAC tumors respond to GPER activation through inhibition of
proliferation, and have dramatic responses to G-1 and αPD-1 immunotherapy similar to
what we have seen in melanoma.
To further examine the tumor suppressive role of GPER signaling in PDAC, the in
vivo studies should be repeated with additional PDAC lines. The 2838c3 was chosen
due to the responsiveness of this tumor line to an established therapeutic regimen, a
combination of αCD40/chemotherapy plus αPD-1 and αCTLA-4 (Winograd et al., 2015).
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Only half of the lines in this PDAC library have immune infiltrate and respond to immunebased therapies; therefore, establishing whether GPER signaling is broadly effective in
all PDAC lines or rather only the lines with immune infiltrate would help to further
understand the therapeutic potential. Further investigation into how the immune infiltrate
is modulated after G-1 treatment may help elucidate the influence of the immune
response to G-1 treatment. In addition, combining G-1 and αPD-1 with other agents like
αCD40, αCTLA-4, or HDAC inhibitors may help identify additional potent combinatorial
therapies that may be effective for PDAC.
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FIGURES

Figure 4.1. GPER activation results in upregulation of histone acetylations. (A) Volcano
plot of histone modifications determined by mass spectrometry after transient estrogen
exposure. Significantly changes CBP/p300 marks are in red. (B) Melanin assay on
melanocytes treated transiently for 4 days with estrogen, CBP/p300 inhibitor C646, or
both over time. (C) Western blot of a CBP/p300 regulated histone acetylation in
melanocytes treated with estrogen, CBP/p300 inhibitor C646, or both. (D) Western blot
of B16F10 melanoma cells treated with G-1, pracinostat, or both. (E) Proliferation assay
of B16F10 melanoma cells treated with G-1, pracinostat, or both. n=3 biologic replicates
for each experiment. Error bars denote +/- s.d.
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Figure 4.2. GPER signaling induces large-scale transcriptional changes. (A) MA plot of
transcripts altered by G-1 treatment in 3 biologic replicates of primary human
melanocytes after DEseq2 analysis. Significantly changes are in red. (B) Gene ontology
analysis (PANTHER) of enriched genes that are either upregulated or downregulated.
(C) Survival analysis of G-1 upregulated genes, when elevated in the melanoma TCGA
data (cBioPortal) (D) Survival analysis of G-1 downregulated genes, when elevated in
the melanoma TCGA data (cBioPortal) (E) Western blot of WM46 cells treated with a
dose response of G-1 for BTG2.
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Figure 4.3. Melanocytes with different levels of constitutive pigmentation proliferate at
different rates. (A) Representative photo of primary human melanocytes with varying
baseline pigmentation. (B) Proliferation and melanin assay of 13 distinct isolations of
melanocytes, error bars = +/- s.d. (C) Representative bright field microscopy images of
light (LMC) and dark (DMC) melanocytes. (D) Western blot for p-RB, RB, and c-Myc for
the 3 darkest and lightest melanocyte isolates. (E) Proliferation assay of the heMel
transduced LMC and DMC isolates. (F) Western blot for markers of proliferation and
melanocyte differentiation in LMC and DMC heMel cells.
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Figure 4.4. Allopregnanolone stimulates melanocyte proliferation. (A) High-throughput
small molecule screen in diBRAFV600E melanocytes. (B) Table of molecules with the
greatest stimulatory effect on proliferation, with and without BRAFV600E induction. (C)
Dose response proliferation assay on normal melanocytes, error bars = +/- s.d. (D)
Proliferation assay on diBRAF melanocytes with allopregnanolone, error bars = +/- s.d.
(E) Proliferation assay comparing estrogen, progesterone, and allopregnanolone, error
bars = +/- s.d. (F) Melanin assay comparing estrogen, progesterone, and
allopregnanolone, error bars = +/- s.d. (G) Tumor weight of B16F10 melanoma tumors
grown for 14 days in male, female, and pregnant female mice, error bars = +/- s.d.
122

Figure 4.5. GPER signaling is tumor suppressive in PDAC. (A) Western blot of a dose
response treatment of 2838c3 PDAC cells with G-1. (B) Western blot of 2838c3 PDAC
cells treated with a pulse or constant 500nM dose of G-1. (C) Proliferation assay of
several PDAC lines treated with 500nM G-1, * denotes p < 0.05, error bars = +/- s.d. (DG) Western blot for p-RB, RB, and c-Myc on several PDAC cell lines (H) Experimental
outline of 2838c3 PDAC-bearing mice treated with vehicle or G-1, as well as isotype
antibody control (2A3) or αPD-1 antibody. Treatment was started at day 7 after tumors
were palpable. n = 5 per group. (H) Tumor volumes after G-1 treatment. (J), Tumor
volumes over time of treatment groups. (K), Survival curve of mice treated with vehicle or
G-1, as well as αPD-1 antibody or isotype antibody control (2A3). Significance between
groups by the Log-Rank (Mantel-Cox) test is listed in the table below.
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CONCLUDING REMARKS
As the technical capabilities for generating data continue to grow exponentially in
the biomedical sciences, it is important not to forget the power of observation.
Biomedical researchers are in an age where it is possible to generate large quantities of
data quickly, but to perform hypothesis-driven research one must first synthesize a
hypothesis. Sometimes it may be easy to forget that beyond the enthusiasm and
excitement revolving around these cutting edge approaches lie the caveats of all
experimental systems; everything we do in the laboratory is artificial to a degree and has
limitations. To that end, turning to clinical observations for initial hypothesis generation
may result in more fruitful research efforts; whether we accept or reject a hypothesis
does not inhibit progress when the initial observation is based in reality instead of in
silico biology. In this dissertation, we have leveraged clear clinical observations to
generate testable hypotheses to learn how sex hormones influence biology of
melanocytes and melanoma, resulting in the identification of a new therapeutic target in
melanoma. While the scope of this work remains relatively narrow, the understanding we
have generated can be applied to several areas of biology, including other areas of
cancer biology, epigenetics, and epidemiology.
In the field of cancer biology, understanding how the immune system influences
disease progression is a blossoming field of research, resulting in clinical development
of many therapeutic agents that target the immune system. Clearly the future of cancer
therapy will include immune-based, combinatorial approaches, but we must not forget
other aspects of biology, including development. Normal human development results in
an estimated 37.5 trillion cells that function in harmony (Bianconi et al., 2013). The
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normal mechanisms of development, cellular differentiation, DNA repair, and immuneclearance prevent the vast majority of these cells from ever transforming into cancer.
Understanding the pathways that regulate cellular differentiation may be leveraged to
drive differentiation in tumor cells and increase the efficacy of immune-based therapies,
as we have shown with GPER signaling in melanoma.
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